



# Article 6S-Like scr3559 RNA Affects Development and Antibiotic Production in Streptomyces coelicolor

Jan Bobek <sup>1,2,\*</sup>, Adéla Mikulová<sup>2</sup>, Dita Šetinová<sup>1</sup>, Marie Elliot<sup>3</sup> and Matouš Čihák<sup>1</sup>

- <sup>1</sup> Institute of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, Studničkova 7, 12800 Prague, Czech Republic; Dita.Setinova@lf1.cuni.cz (D.Š.); matous.cihak@lf1.cuni.cz (M.Č.)
- <sup>2</sup> Faculty of Science, Jan Evangelista Purkyně University in Ústí nad Labem, České mládeže 8, 40096 Ústí nad Labem, Czech Republic; adimiky@gmail.com
- <sup>3</sup> Department of Biology, McMaster University, Hamilton, ON L8S 4K1, Canada; melliot@mcmaster.ca
- \* Correspondence: jan.bobek@lf1.cuni.cz

**Abstract:** Regulatory RNAs control a number of physiological processes in bacterial cells. Here we report on a 6S-like RNA transcript (*scr3559*) that affects both development and antibiotic production in *Streptomyces coelicolor*. Its expression is enhanced during the transition to stationary phase. Strains that over-expressed the *scr3559* gene region exhibited a shortened exponential growth phase in comparison with a control strain; accelerated aerial mycelium formation and spore maturation; alongside an elevated production of actinorhodin and undecylprodigiosin. These observations were supported by LC-MS analyses of other produced metabolites, including: germicidins, desferrioxamines, and coelimycin. A subsequent microarray differential analysis revealed increased expression of genes associated with the described morphological and physiological changes. Structural and functional similarities between the *scr3559* transcript and 6S RNA, and its possible employment in regulating secondary metabolite production are discussed.

Keywords: small RNA; 6S RNA; Streptomyces; antibiotics; secondary metabolism

# 1. Introduction

Streptomycetes are Gram-positive soil-dwelling bacteria. The soil niche represents a harsh living environment where the natural microbial inhabitants have evolved various nutrient-acquiring and life-defending strategies. *Streptomyces* have a complex developmental life cycle that begins with germinating spores. They then form branching vegetative hyphae that differentiate into aerial mycelium and spores again [1–4]. Moreover, the streptomycetes possess extraordinary genetic equipment for sensing extracellular signals and producing various specialized metabolites [5]. Among other applications, these molecules encompass over two-thirds of the clinically useful antibiotics and other compounds of industrial value [6]. The developmental complexity and antibiotic biosynthesis of these organisms require a complex regulatory network, which is responsible for addressing proper responses to changes in environmental conditions [7].

In order to achieve such responses, a number of pleiotropic regulators are involved in the gene expression control of the streptomycetes. So-called regulatory RNAs represent one such regulatory sphere. A single RNA molecule may regulate multiple genes, thus broadly influencing the physiology of the cell [8]. These RNAs act either simply by base-pairing with target nucleotides, or by binding target proteins via their secondary structures. 6S RNA achieves gene regulation using the second strategy and is one of the best studied regulatory RNAs in bacteria [9]. 6S RNA has a direct influence on the transition between developmental stages thanks to its direct association with the sigma70-RNA polymerase holoenzymes (RNAP-HrdB in *Streptomyces*). The formation of such complexes interferes with exponential phase-specific transcription [10–12]. Due to its function, the promoter-like secondary structure of 6S RNA is highly conserved across the bacterial kingdom. This high



Citation: Bobek, J.; Mikulová, A.; Šetinová, D.; Elliot, M.; Čihák, M. 6S-Like scr3559 RNA Affects Development and Antibiotic Production in *Streptomyces coelicolor*. *Microorganisms* **2021**, *9*, 2004. https://doi.org/10.3390/ microorganisms9102004

Academic Editor: Carlos García-Estrada

Received: 6 September 2021 Accepted: 16 September 2021 Published: 22 September 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). degree of conservation has enabled the identification of more than 100 potential 6S RNA homologues in diverse eubacterial species, using computational searches [13]. Notably, however, *Streptomyces* were absent among those species in which 6S RNA was identified.

We had developed a bioinformatic tool that detected two streptomycete 6S-like transcripts whose secondary structures exhibited convincing similarity with those of 6S RNAs found in other bacteria [14,15]. Subsequently, it was shown that a null mutation of one of these genes (*scr3559*), affected actinorhodin production in *S. coelicolor* [16]. To analyze the effect of the scr3559 RNA on cell morphology and physiology, we constructed a strain that over-expresses *scr3559*, with its gene placed under the control of a thiostrepton-inducible promoter. Interestingly, the levels of the scr3559 RNA were consistent with a strong effect on the exponential growth of *S. coelicolor*, as well as on its secondary metabolite production. This suggests that the scr3559 RNA functions as an important developmental regulator.

# 2. Materials and Methods

#### 2.1. Strains, Media and Conditions of Cultivation

*Streptomyces coelicolor* M145 was used as a model wild type strain, as well as the parental strain used to construct a strain that over-expresses the *scr3559* gene. The resulting *S. coelicolor* strains, *Escherichia coli* strains, and all plasmids/cosmids used in this study are summarized in Table 1.

*E. coli* strains were grown at 37 °C on solid agar and in LB liquid medium [17]. *Streptomyces* strains (10<sup>8</sup> spores) were grown at 30 °C on the solid agar media soya flourmannitol (MS), supplemented minimal (SMMS) [18], and Oxoid Nutrient Agar (ONA, OXOID CZ s.r.o, Thermo Fisher Scientific, Brno, Czech Republic) or in liquid rich with glucose, unless otherwise stated, media (R3) [19] or minimal NMMP [18].

Strain or Plasmid	Genotype, Description or Use	Reference or Source	
S. coelicolor			
M145	45 SCP1-SCP2-		
C6S	<i>scr3559</i> over-expression: in order to be expressed from the <i>tipA</i> promoter, the <i>scr3559</i> gene was cloned into the high copy number plasmid pCJW93.	This work	
C0	a control strain containing an empty pCJW93 vector	This work	
E. coli			
DH5a	Plasmid construction and general subcloning	Invitrogen	
ET12567/pUZ8002	ET12567/pUZ8002 Generation of methylation-free plasmid DNA and conjugation from <i>E. coli</i> into <i>S. coelicolor</i>		
Plasmids/cosmids			
pIJ2925	General cloning vector	[21]	
pCJW93	pCJW93 High-copy-number <i>E. coli/Streptomyces</i> plasmid containing a thiostrepton inducible ( <i>tipA</i> ) promoter		
StH5	S. coelicolor cosmid containing the scr3559 gene	[23]	

Table 1. Bacterial strains and plasmids used in this study.

# 2.2. Construction of High-Copy-Number Vector Overexpression Strains

The over-expression strain used in this study was constructed using the actinomycete high-copy-number shuttle vector pCJW93 (Table 1). The *scr3559* gene from *S. coelicolor* was PCR amplified from cosmid StH5 (Table 1) using primers 6SO/E1 (GTGCGCGCCT-GTCCGCGCTTG) and 6SO/E2 (GCCGATCGGTCGTCGGTTCGC), and the product was inserted into pIJ2925 (Table 1) using a rapid DNA ligation kit (Roche, Merck Life Science spol. s r.o., Prague, Czech Republic). The construct was transformed into DH5 $\alpha$  *E. coli* cells (Table 1). The *scr3559*-containing fragment was cut out from the plasmid with BgIII

and subcloned into the BamHI site of the over-expression vector pCJW93, downstream from the thiostrepton-inducible (*tipA*) promoter. The plasmid was passaged through the non-methylating *E. coli* strain ET12567/pUZ8002 (Table 1) before being introduced into *S. coelicolor* M145 by conjugation [18], resulting in the construction of the C6S over-expression strain. A control strain, C0, containing the pCJW93 vector lacking any insert was constructed simultaneously.

#### 2.3. Mapping of 5' Ends

The 5' rapid amplification of cDNA ends (5' RACE) was performed using the FirstChoice<sup>®</sup> RLM RACE kit (Invitrogen, Thermo Fisher Scientific, Brno, Czech Republic) with minor modifications, as described in [24]. Total RNA was extracted from a plasmid-free strain of *S. coelicolor* that had been cultivated for 72 h in NMMP liquid medium.

RNA quality was assessed by determining the RNA-integrity number (RIN) and only those samples with a RIN higher than 7 were further analyzed. Ten micrograms of RNA were treated with tobacco acid pyrophosphatase (TAP) before being ligated to a 5' RACE adapter using T4 RNA ligase. The obtained product was used as template for reverse transcription using 50  $\mu$ M of random decamers and M-MLV reverse transcriptase.

The resulting cDNA served as a template for 5' end PCR amplification using an outer adaptor-specific oligonucleotide and an oligonucleotide complementary to the scr3559 RNA sequence (CGCTTACTCGGGACCGGT). The PCR product was used as a template for a second PCR reaction using an inner adaptor-specific oligonucleotide and an inner 'nested' scr3559 RNA-complementary primer (6SR; ACCGGTATACAAAGGACTCAACGG). The second PCR product was separated on an agarose gel and eluted using the QIAquick-Gel Extraction kit (Qiagen, GeneTiCA s.r.o., Prague, Czech Republic). The purified products were cloned into the TOPO<sup>®</sup> vector using TOPO TA Cloning<sup>®</sup> (Invitrogen) and transformed into TOP10F competent cells (Invitrogen). Plasmid DNA was extracted from cells containing cDNA inserts using the QIAprep<sup>®</sup> Miniprep kit (Qiagen), and the cloned inserts were sequenced using M13 primers.

#### 2.4. Differential Expression Analyses (Northern Blot)

At indicated time points of cultivation in the NMMP liquid medium (with thiostrepton supplemented at 50  $\mu$ g/mL), cells were harvested and RNA was isolated as described in [25]. UV spectroscopy and agarose gel electrophoresis were used to assess the quantity and quality of total RNA samples. Total RNA samples were separated on 6% denaturing polyacrylamide gels and were transferred to nylon membranes (BioRad s.r.o., Prague, Czech Republic) using a Trans-Blot semi-dry transfer cell (BioRad) (25 V, 4 °C overnight). The membrane was then UV-cross linked before being hybridized with the 5′-end-labeled oligonucleotide 6SR (ACCGGTAGTACAAAGGACTCAACGG), which corresponded to an internal segment of the scr3559 RNA. The hybridization was performed overnight at 42 °C in ULTRA hybridization buffer (Invitrogen). The detection and quantification of signals were conducted using a phosphorimager (BioRad).

#### 2.5. Secondary Metabolite Production Assays

To quantify the actinorhodin and undecylprodigiosin levels in the C6S strain relative to the C0 strain,  $10^8$  spores of each were inoculated into NMMP liquid medium (with thiostrepton supplemented at 50 µg/mL). Cultures were shaken at 30 °C and samples were taken after 48, 72, and 144 h (unless otherwise stated). Actinorhodin and undecylprodigiosin levels were then quantified as described [26] and amounts were normalized per cell concentration.

## 2.6. Liquid Chromatography-Mass Spectrometry (LC-MS) Assay

Both C0 and C6S strains were cultivated for 48 h in R3 medium containing thiostrepton (50  $\mu$ g/mL). Secondary metabolites were extracted from the culture supernatants using solid phase extraction [27,28]. LC-MS analyses were performed on the Acquity

UPLC system with 2996 PDA detection system (194–600 nm) connected to LCT premier XE time-of-flight mass spectrometer (Waters Gesellschaft m.b.H., Prague, Czech Republic). Five microliters of the sample were loaded onto the Acquity UPLC BEH C18 LC column (50 mm × 2.1 mm I.D., particle size 1.7  $\mu$ m, Waters) at 40 °C and eluted with a two-component mobile phase, A and B, consisting of 0.1% formic acid and acetonitrile, respectively, at the flow rate of 0.4 mL min<sup>-1</sup>.

The analyses were performed under a linear gradient program (min/%B) 0/5; 1.5/5; 15/70; 18/99 followed by a 1.0-min column clean-up (99% B) and 1.5-min equilibration (5% B). The mass spectrometer was operated in the positive "W" mode with capillary voltage set at +2800 V, cone voltage +40 V, desolvation gas temperature, 350 °C; ion source block temperature, 120 °C; cone gas flow, 50 L h<sup>-1</sup>; desolvation gas flow, 800 L h<sup>-1</sup>; scan time of 0.15 s; inter-scan delay of 0.01 s. The mass accuracy was kept below 6 ppm using lock spray technology, with leucine enkephalin being used as the reference compound (2 ng  $\mu$ L<sup>-1</sup>, 5  $\mu$ L min<sup>-1</sup>). MS chromatograms were extracted for [M + H]<sup>+</sup> ions with the tolerance window of 0.03 Da, smoothed with a mean smoothing method (window size; 4 scans, number of smooths, 2). The data were processed by MassLynx V4.1 (Waters).

#### 2.7. Microarrays

Cultivation of the C6S and control C0 strains was performed in duplicate.  $10^8$  spores were inoculated into NMMP liquid medium (with thiostrepton at 50 µg/mL) and shaken at 30 °C. Cells were harvested after 72 and 144 h and the quality of the isolated RNA samples was determined by their RIN. Only those samples whose RIN was >7 were sent to the Oxford Gene Technology Company (OGT, Oxford, United Kingdom), where microarray analysis was performed as follows: the RNA samples were used as template for reverse transcription using random hexamer primers and Cy3/Cy5 dyes (swapped in the duplicates); the labeled cDNAs were hybridized on microarray slides containing  $4 \times 44,000$  spotted oligonucleotides, mapped preferentially to the ORFs of the *S. coelicolor* genome. The differential expression was estimated using the binary logarithm of the ratio of the expression level in the test C6S sample to the level of expression in the control C0 sample.

#### 3. Results


#### 3.1. Size and Gene Position of the scr3559 Transcript

The scr3559 RNA (also called Sc2 in [15] or 6S RNA in [16]) is a 192 nt long transcript that folds into a 6S-like secondary structure [16]. Its gene is located between *SCO3558* and *SCO3559*. It is noteworthy that it is oriented downstream of *SCO3559*, as illustrated here in Figure 1 (minus strand) and is in accordance with the RNA sequence shown in both the above-mentioned publications, although the gene is mistakenly depicted in the opposite direction in Mikulík et al. [16], where it is dubbed *ssrS*.



Figure 1. Revised scr3559 gene orientation, relative to its flanking genes.

To precisely map the *scr3559* transcription start site, a RACE experiment was performed using internal nested primers complementary to the scr3559 RNA. Two RT-PCR products were detected and sequenced (Figure 2). These corresponded to a nascent (pre-scr3559 RNA) and a processed transcript (scr3559 RNA) of sizes 260 and 192 bases, respectively. The transcription start site is thus located at genome position 3934888, whereas the processed 6S-like form, as presented previously, begins at position 3934820. Based on these results, secondary structures of precursor (pre-scr3559 RNA), processed (scr3559 RNA) and excised




transcripts were modeled using the RNAfold algorithm (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi, accessed on 1 September 2021) [29] (Figure 2b).

(b)

**Figure 2.** (a) 5' RACE analysis. From the left: lanes 1–3 PCR products from the RACE experiment, taken from 72, 144, and 168-h-old cultures; lanes 4–5 RTase-free and ligase-free negative controls (no signals). The arrows point to those PCR products whose sequences correspond to the nascent scr3559 RNA (260 bases) and to the processed form (192 bases). The molecular sizes of the RACE-generated PCR products roughly corresponded to the sizes of the whole transcripts. (b) Secondary structure predictions for the 260 nt pre-scr3559 RNA, a processed 192 nt form and the excised 68 nt transcript. The structures were modeled using RNAfold software with energy parameters scaled to 30 °C. The scissors mark the predicted site of cleavage in the precursor transcript. The green and blue clouds indicate the 5' and 3' ends of scr3559 RNA, respectively.

#### 3.2. scr3559 RNA Expression Profiles (Northern Blotting)


scr3559 RNA levels were monitored throughout development for both the control C0 strain and the mutant C6S strain. Cells were cultivated in liquid NMMP medium and harvested after 12 h (early exponential phase of growth), 48 h (late exponential phase of growth) and 72 h of cultivation (stationary phase). No signal was detected in samples from the early exponential phase (not shown). A signal corresponding with pre-scr3559 RNA (260 nt) was detected only in the older cells of the C0 strain, whereas it is clearly seen in both developmental time points in the C6S over-expression strain (Figure 3). In both strains, the processed scr3559 RNA could only be detected during the exponential to stationary phase transition, when 6S RNA is expected to be active.




**Figure 3.** Northern blot analysis of scr3559 RNA levels in C0 and C6S strain. The product at about 250 nt likely corresponds to the pre-scr3559 RNA. The processed scr3559 RNA (192 nt) could be seen only in 48 h-old cells of both C0 and C6S strains.

#### 3.3. Phenotypic Analyses

After cultivation in NMMP medium with the selective antibiotic thiostrepton, the production of actinorhodin and undecylprodigiosin metabolites were measured and normalized per cell concentration. The dry weight of the cells was estimated after they were collected in spin columns (Qiagen), centrifuged and washed with ethanol. Elevated antibiotic production, actinorhodin (blue) and undecylprodigiosin (red) were repeatedly detected in the C6S overexpression strain, compared with the C0 control strain (Figure 4).




(a)




**Figure 4.** Liquid culture phenotypes: (**a**) The C0 control (left) and C6S (right) strains after 72 h of cultivation in NMMP liquid medium. (**b**) Comparison of actinorhodin production in C0 and C6S strains; the *y*-axis indicates absorbance at  $A_{640} \times 100$  and normalized per cell concentration. The error bars represent a confidence interval from at least four independent biological replicates ( $\alpha = 0.2$ ). (**c**) Comparison of undecylprodigiosin production in C0 and C6S strains; the *y*-axis indicates absorbance at  $A_{530} \times 100$  and normalized per cell concentration. The error bars represent a confidence interval from at least four independent biological replicates ( $\alpha = 0.2$ ).

When cultivated on solid agar plates containing thiostrepton (R2YE, SMMS, MS), the C6S strains revealed differences in morphology (small colonies, aberrant mycelium formation, less biomass, and more rapid sporulation compared to the C0 control), and exhibited increased production of secondary metabolites (mainly blue actinorhodin) (Figure 5a). This observation was supported by the data collected using electron microscopy to compare the morphology of C6S and C0 control strains grown in the presence of thiostrepton. The pictures clearly show the accelerated development of the aerial mycelium for the C6S strain (Figure 5b).



(a)




(b)

**Figure 5.** Solid culture phenotypes: (a) The C6S (left) and C0 control (right) strains after 120 h of cultivation on MS medium. (b) Electron-micrographs of mycelia from the C6S (left) and C0 (right) strains after 120 h of cultivation on solid MS medium.

When cultivated on solid MS plates with apramycin and a gradient of thiostrepton, actinorhodin was visibly over-produced by the C6S strain only in the areas with higher concentrations of thiostrepton. In this area, growth of the C6S strain was slower, its cell density was lower and colonies were tiny and grey, suggesting that vegetative growth may be suppressed, and sporulation may be accelerated.

Growth in the area that did not contain thiostrepton (i.e., the *tipA* promoter is not induced and *scr3559* is not overexpressed) looked similar to that of the C0 control strain, which did not show any phenotypic differences on the same thiostrepton gradient on MS medium. When cultivated on ONA medium with an equivalent thiostrepton gradient, the C6S strain produced visibly more actinorhodin throughout the entire plate. Only in the area with the highest thiostrepton concentrations, actinorhodin was overproduced in both



strains. (Figure 6). This supports our assertion that overexpressing *scr3559* (in response to thiostrepton induction) leads to profound phenotypic changes.


**Figure 6.** The C6S and C0 strains on MS and ONA medium with a linear concentration gradient of thiostrepton  $(0-25 \ \mu L \ mL^{-1}$  respectively to the blue wedge shown to the right of the plates) after 120 h of cultivation. The dashed line indicates where the thiostrepton gradient begins (most concentrated area is at the top of the image).

## 3.4. LC-MS Analysis of Other Metabolite Production

After both C6S and C0 strains had been cultivated for 48 h in R3 liquid medium, supernatants were subjected to LC-MS analysis. No qualitative changes were observed in the production of secondary metabolites, but quantitative differences were detected. Besides the already described increased production of actinorhodin and undecylprodigiosin, other metabolites were detected in both strains. These include germicidins (A, B), desferrioxamines (B, E, G1), and coelimycin P1.

## 3.4.1. Germicidins


The LC-MS data qualitatively confirmed the presence of germicidin A (tR = 6.48 min) and germicidin B (tR = 5.91 min). The acquired m/z 197.1193 corresponded to the  $[M + H]^+$  of germicidin A with a theoretical m/z 197.1178. Based on a comparison of the area under the curve (AUC), six times higher production of germicidin A was observed in C6S (AUC<sub>C6S</sub> = 1252) compared with the C0 strain (AUC<sub>C0</sub> = 206) (Figure 7). Germicidin B was also produced at higher levels in the C6S strain as well, although its levels were not as strikingly enhanced relative to that of germicidin A (AUC<sub>C6S</sub> = 336 and AUC<sub>C0</sub> = 90). The acquired m/z 183.1031 corresponded to the  $[M + H]^+$  of germicidin B with a theoretical m/z 183.1021.



**Figure 7.** Extracted LC-MS chromatograms of germicidin A produced by *S. coelicolor* C6S and C0 after 48 h of cultivation in R3 medium.

#### 3.4.2. Desferrioxaomines

Desferrioxamine B was detected at tR = 3.14 min. The acquired m/z 561.3614 corresponded to the [M + H]<sup>+</sup> of desferrioxamine B with a theoretical m/z 561.3625. The production of this metabolite during the cultivation in R3 with glucose was higher in C6S (AUC<sub>C6S</sub> = 173) than in C0 (AUC<sub>C0</sub> = 110) (Figure 8). A similar trend was seen for the production of desferrioxamine E (AUC<sub>C6S</sub> = 208 vs. AUC<sub>C0</sub> = 139) and G1 (AUC<sub>C6S</sub> = 34 vs. AUC<sub>C0</sub> = 21). Desferrioxamine E was detected at tR = 4.72 min. The acquired m/z 601.3546 corresponded to the [M + H]<sup>+</sup> of desferrioxamine E with a theoretical m/z 601.3561. Desferrioxamine G1 was also detected (tR = 3.28; m/z 619.3663), although the differences between the C6S and C0 strains were subtle.




**Figure 8.** Extracted LC-MS chromatograms of desferrioxamine B produced by *S. coelicolor* C6S and C0 after 48 h of cultivation in R3 medium.

# 3.4.3. Coelimycin P1

We also confirmed the presence of coelimycin P1 (tR = 7.48), an unusual polyketide alkaloid produced by *S. coelicolor* [30]. The acquired m/z 349.1222 corresponded to the  $[M + H]^+$  of coelimycin P1 with a theoretical m/z 349.1229. Traces of this substance were detected when culturing both strains in R3 liquid medium with glucose (AUC<sub>C6S</sub> = 21 vs. AUC<sub>C0</sub> = 8) (Figure 9). However, when we used glycerol instead of glucose as an energy source in the R3 cultivation medium, the production of coelimycin was apparent only in the C6S strain (AUC<sub>C6S</sub> = 139).

#### 3.5. Microarray Transcriptional Analysis

Microarray analysis was performed on C0 and C6S cells grown in liquid NMMP medium. Since previous expression analysis had shown higher levels of scr3559 RNA at later stages of growth, two stages of cell development were investigated: 72 h (younger cells), corresponding to early stationary phase (transition from exponential growth phase, when antibiotic production typically initiates) and 144 h (older cells), corresponding to late stationary stage. Genes that exhibited differential changes in expression are summarized in Table 2 and discussed below.



**Figure 9.** Extracted LC-MS chromatograms of coelimycin P1 produced by *S. coelicolor* C6S and C0 after 48 h of cultivation in R3 medium with glucose or glycerol.

**Table 2.** Color heat map represents the range of gene expression change in the C6S strain relative to the C0 strain from most down-regulated (dark purple) to most up-regulated (dark maroon) genes.

	Average Differential Expression (C6S/C0)		o (o 11).		
Gene SCO Number	Young Cells (72 h)	Old Cells (144 h)	Gene/Cosmid Name	Protein/Gene Cluster	
185	-2.71	3.66	crtB/SCJ1.34	putative geranyl pyrophosphate synthase/Isorenieratene	
186	-0.15	1.85	crtE/SCJ1.35	putative phytoene dehydrogenase (putative secreted protein)/Isorenieratene	
187	-0.82	2.53	crtI/SCJ1.36	putative phytoene synthase/Isorenieratene	
188	-0.41	1.52	crtV/SCJ1.37	putative methylesterase/Isorenieratene	
189	-0.84	1.14	crtU/SCJ1.38c	putative dehydrogenase/Isorenieratene	
190	0.02	1.20	crtT/SCJ12.02c	İsorenieratene	
191	-0.76	1.11	crtY/SCJ12.03c	Isorenieratene	
216	-1.27	2.72	narG2	nitrate reductase alpha chain NarG2	
217	-1.61	2.69	narH2	nitrate reductase beta chain NarH2	
379	1.49	1.05	katA/EC 1.11.1.6	catalase KatA	
380	0.91	2.10	SCF62.06	conserved hypothetical protein	
381	2.37	2.30	SCF62.07	putative glycosyl transferase	
382	3.14	0.82	SCF62.08	UDP-glucose/GDP-mannose family dehydrogenase	
383	2.24	1.66	SCF62.09	hypothetical protein	
384	2.01	1.58	SCF62.10	putative membrane protein	
385	1.74	1.23	SCF62.11	putative membrane protein	
409	1.77	1.14	sapA/SCF51.08c	spore-associated protein precursor	

Gene SCO Number         Twong Cells (72 h)         Old Cells (144 h)         Gene Cosmid Name         Patein/Gene Cluster           469 $327$ $422$ $5274.06$ ;         Cosmid Name         publics; addrephone codichelin           479 $-1.37$ $-333$ SCFM.10;         publics; addrephone codichelin           481 $-233$ $-373$ SCFM.10;         publics; addrephone codichelin           484 $-233$ $-433$ SCFM.10;         publics; addrephone codichelin           484 $-233$ $-436$ SCFM.11;         publics; addrephone codichelin           484 $-233$ $-436$ SCFM.11;         publics; addrephone binding           496 $-1.32$ $-1.66$ SCFM.13;         publics; addrephone binding           497 $-0.40$ $-2.20$ SCFM.16;         publics; addrephone binding           498 $-0.66$ $-3.23$ SCFM.16;         publics; addrephone codichelin           498 $-0.67$ $-1.32$ $0.57$ $0.67$ $0.64$ 2777 $1.82$ $0.24$ $0.24$ $0.24$ $0.24$ 2784 <t< th=""><th></th><th colspan="2">Average Differential Expression (C6S/C0)</th><th></th><th></th></t<>		Average Differential Expression (C6S/C0)			
979 $\lambda_1$ $\lambda_2$ $\lambda_1$ $\lambda_2$ $\lambda_1$ $\lambda_2$ $\lambda_2$ $\lambda_1$ $\lambda_2$	Gene SCO Number	Young Cells (72 h)	Old Cells (144 h)	Gene/Cosmid Name	Protein/Gene Cluster
490-2.18-3.53SCT3 1/6putative extenses/statepriner concluded491-1.57-3.33SCT3 1/6putative extenses/statepriner concluded492-0.98-3.27SCT3 1/16putative printse printses/statepriner concluded493-1.66-4.03SCT3 1/16putative printse printses/statepriner concluded494-2.85-1.45SCT3 1/16putative printse printses/statepriner495-1.32-1.06SCT3 1/16putative invasion printses/statepriner4960.61-2.29SCT3 1/16putative invasion printses/statepriner497-0.40-2.20SCT3 1/16putative invasion printses/statepriner498-0.96-6.18SCT3 1/17putative invasion printses/statementare499-2.28-4.18SCT3 1/16putative invasion printses/statementare499-2.28-4.18SCT3 1/16Not printses/statementare499-2.200.74-1.22o.37112-0.37entitive (M/17, CAR06)Not printses/statementare2084-0.97-1.23o.47124-0.37entitive (M/17, CAR06)Not printses/statementare2084-0.97-1.30entitive (M/17, CAR06)2084-0.97-1.30entitive (M/17, CAR06)2084-0.97-1.30entitive (M/17, CAR06)2084-0.97-1.30entitive (M/17, CAR06)2084-0.97-2.30entitive (M/17, CAR06)2085-0.97	489	-3.72	-6.22	SCF34.08c	
191         -1.00         -2.33         -2.34         -2.34         -2.34         -2.34         -2.34         -2.34         -2.34         -2.34         -2.34         SCF34 L12         protent/Siderophere coll-chain	490	-2.18	-3.35	SCF34.09c	putative esterase/Siderophore coelichelin
492         -0.88         -5.73         SCTM 11c         putative period. with w AB-characterization collichem           496         -1.66         SCTM 12c         putative and characterization and the analysis of the analysis analysis of	491	-1.57	-3.33	SCF34.10c	
2001.001.001.001.001.00494-285-1.00SCFM.13:protein/Siderophore binding495-1.32-1.66SCFM.14:ATP-binding protein/Siderophore actil-binding4960.61-2.29SCFM.15:protein/Siderophore actil-binding497-0.60-2.20SCFM.16:protein/Siderophore actil-binding498-0.96-2.00SCFM.16:protein/Siderophore actil-binding499-2.23-0.05SCFM.16:protein/Siderophore actil-binding499-2.23-0.25bind/SCM.25:protein/Siderophore actil-binding499-2.24-1.25bind/SCM.25:bind/SCM.25:277-1.220.55bind/SCM.25:bind/SCM.25:284-2.100.74mutd'/SCAL0.17:protein/Siderophore actil-binding284-1.12-1.23bind/SCAL0.17:protein/Siderophore2781-1.12-1.20SCCC.02bind/SCAL0.17:2782-0.07-0.29SCCC.01protein/Siderophore2784-1.12-1.20SCCC.01protein/Siderophore2784-1.12-1.20SCCC.01protein/Siderophore2784-0.61-4.81SCCC.01protein/Siderophore2784-0.61-4.81SCCC.01.13protein/Siderophore2784-0.61-4.81SCCC.01.14protein/Siderophore2784-0.61-4.81SCCC.05.15protein/Siderophore2785-2.22-	492	-0.88	-3.73	SCF34.11c	putative peptide synthetase/Siderophore coelichelin
494         -2.85         -1.16         SCFM 13: The main system control in a main system contro	493	-1.66	-4.03	SCF34.12c	
94 $L29$ $L06$ $CLSL M_{c}$ ipportent Skerphore coelicbin965 $-1.32$ $-1.66$ $SCFR.14$ $ATT-Mining relative transiderphore A& transportationane967-0.49-2.29SCFR.14ATT-Mining relative transiderphore coelicbin968-0.49-2.20SCFR.14PUttive transiderphore coelicbin969-2.28-1.81SCFR.118PUttive transiderphore permease transmembrane967-0.37-0.23hR/2SCM128PRN patheterizes principal sigm factor FIAC968-2.28-1.22cRNPUttive transferase principal sigm factor FIAC969-2.28-0.37-0.23hR/2SCM128RN patheters principal sigm factor FIAC969-2.28-0.37-0.23hR/2SCM128RN patheters principal sigm factor FIAC977-1.220.58hR/2SCM128RN patheters principal sigm factor FIAC984-2.100.74nurd/SCA41017Puttive transferase MurG24311.15-0.88d\mu/4/SCCA202A5A779-9.860.99hd/4/SCCA202A5A779-9.67-2.394SCC105.11puttive transferase MurG7784-0.41-4.29SCC105.12puttive transferase MurG7784-0.41-4.39SCC105.14puttive transferase herd Patheterinsamine7784-0.42-3.73SCI05.14puttive transferaterinsamine7785-2.29$					
995 $-1.52$ $-1.00$ SCNA14cATP-binding protein/Siderophone collchelin9960.61 $-2.29$ SCFA15cprotein/Siderophone collchelin997 $-0.40$ $-0.06$ $-6.16$ SCFA15cprotein/Siderophone collchelin998 $-0.96$ $-6.16$ SCFA17ccollchelinputtive inseldeophone collchelin999 $-2.25$ $-4.18$ SCFA17ccollchelinputtive inseldeophone collchelin997 $-2.25$ $-4.18$ SCFA17ccollchelinputtive inseldeophone collchelin998 $-0.57$ $-0.57$ $hdt/SCA10.12c$ puttive inseldeophone collchelin1897 $-2.21$ $-0.57$ $hdt/SCA10.12c$ puttive inseldeophone collchelin2984 $-2.10$ $0.74$ $mmG/SCA10.17c$ puttive inseldeophone collchelin241 $1.15$ $-0.88$ $hdt/SCC2.02c$ $hdt/SCC2.02c$ 2781 $-1.12$ $-2.95$ SCCI05.11puttive inseldeophone collchelin2782 $-0.07$ $-3.94$ SCCI05.12puttive inseldeophone collchelin2784 $-0.45$ $-2.92$ SCCI05.13quative servidg Divelenciannines2784 $-0.45$ $-2.92$ SCCI05.14quative servidg Divelenciannines2784 $-0.45$ $-2.92$ SCCI	494	-2.85	-4.16	SCF34.13c	lipoprotein/Siderophore coelichelin
950.01-2.20SCFM 10cprotein/Steephore celichelin497-0.40-2.20SCFM 10cprotein/Steephore celichelin498-0.96-6.16SCFM 10cprotein/Steephore celichelin499-2.28-4.08SCFM 18cprotein/Steephore celichelin499-2.28-4.08SCFM 18cprotein/Steephore celichelin499-2.28-4.08SCFM 18cprotein/Steephore celichelin499-2.24-1.220.55htt//SCM 12kc2077-1.220.55htt//SCM 12kccelalamin insynthesis protein Cobs2184-2.100.74nurG/SCA 10.10cprotein/Steephore celichelin2184-2.100.74nurG/SCA 10.10cprotein/Steephore/ste	495	-1.32	-1.66	SCF34.14c	ATP-binding protein/Siderophore coelichelin
497-0.40-2.20S.T.9.16protein concovery case Siderophore colichelin putative peptide monocovery case Siderophore colichelin putative period monocovery case Siderophore colichelin putative formy transferate/Siderophore colichelin 	496	0.61	-2.29	SCF34.15c	protein/Siderophore coelichelin
1991.0.92.1.9.1/CControl199-2.28-1.031.0.9School 1001895-0.57-0.25InfC/SCM1.28RNA polymerase principal signal factor HalC2077-1.220.55driv1/SCM1.28RNA polymerase principal signal factor HalC2084-2.100.74murG/SCA1.017public to Environment Principal signal factor HalC21311.15-0.88driv1/SCA1.017public to Environment Principal signal factor HalC2284-2.100.74murG/SCA1.017public to Environment Principal signal factor HalA23111.15-0.88driv1/SCA1.017public to Environment Principal signal factor HalA27909.060.30murG/SCA1.012public to Environment Principal signal factor HalA2781-1.12-1.20SCC105.12public to Environment Principal signal factor HalA2783-0.07-3.94SCC105.13decatoroystase/Desterritoxamines2783-0.45-4.30SCC105.13decatoroystase/Desterritoxamines2785-0.61-4.30SCC105.14public acylinaterape/Desterritoxamines2785-0.66-0.71SCF1.19public acylinaterape/Desterritoxamines2785-0.86-0.71SCF1.19public acylinaterape/Desterritoxamines2785-0.86-0.71SCF1.19public acylinaterape/Desterritoxamines2785-0.86-0.71SCF1.19public acylinaterape/Desterritoxamines2785-0.86-0.71SCF2.19public acyli	497	-0.40	-2.20	SCF34.16c	protein/Siderophore coelichelin
99-2.28-4.08SCT3-18puttive form/Itensferaze/Sideophore coelichelin985-0.25-0.25RNA polymerses principal sigma factor HIAC1849-2.84-1.28 $coN$ DivIVA2077-1.220.55 $coN$ DivIVA2084-2.100.74 $muG/SCAA10.7c$ $puttive UDP.Nactrylghcosamine N-2084-2.100.74muG/SCAA10.7cputtive UDP.Nactrylghcosamine N-2084-1.17-0.08ah/A/SCCA40cAhA24311.15-0.08ah/A/SCCA10cAhA24450.980.31th/A/SCAA10.7cAhA2779-1.17-2.39SCC105.11puttive secretic protein/Desferitoxamines2781-1.12-1.20SCC105.13deprotein/Desferitoxamines2783-0.45-4.43SCC105.13puttive acyltranatines2784-0.61-4.43SCC105.15puttive acyltranatines2785-1.22-1.63SCC105.15puttive acyltranatines2784-0.61-4.43SCC105.15puttive acyltranatines2785-1.22-1.63SCC105.15puttive acyltranatines2784-0.61-4.43SCC105.16puttive acyltranatines2785-1.22-1.63SCE10.32protein/Desferrioxamines2784-0.61-4.43SCC105.16puttive acyltranatines2785-1.22-1.64SCE10.32protein288722-1.63SCE10.32puttive ac$	498	-0.96	-6.16	SCF34.17c	
1849-2.34-1.28 $cbN$ $cbN$ $cbN$ $cbN$ 2077-1.220.55 $dbWA/SCA10.17c$ $cbMA/SCA10.17c$ $cbMA/SCA10.17c$ $cbMA/SCA10.17c$ 2084-2.100.74 $muC/SCA10.17c$ $cbMA/SCA10.17c$ $cbMC/SCA10.17c$ 24111.15-0.880.31 $bMA/SCA240.2c$ $maC/SCA10.17c$ $act/Ma/SCA3.0c/Ma/SCA240.2c$ 2779-1.17-2.95SCC105.11 $act/A/A/SCA3.0c/Ma/SCA240.2c$ $act/A/A/SCA3.0c/Ma/SCA240.2c$ 2781-1.12-7.00SCC105.12 $act/A/A/SCA3.0c/Ma/SCA240.2c$ $act/A/A/SCA3.0c/Ma/SCA240.2c$ 2782-0.07-3.94SCC105.13 $act/A/A/SCA240.2c$ 2783-0.45-4.20SCC105.13 $act/A/A/SCA240.2c$ 2784-0.61-4.83SCC105.13 $act/A/SCA240.2c$ 2784-0.64-4.83SCC105.14putative secred protein/Desferrioxamines2784-0.63-4.20SCC105.15 $act/A/A/SCA240.2c$ 3110-2.28-5.29SCC105.14putative acervica/mines3220-2.33-2.27 $bM/S/SCA21.0c$ $bKAA$ 32310.36-0.71SCE15.4cputative secred protein AbeB3232-2.021.164SCE15.16putative secred protein AbeB32310.392.31SCE15.4cputative secred protein AbeB3232-2.021.164SCE15.4cputative secred protein AbeB3232-2.27-1.63SCE15.7cputative acerborden acerborden AbeB <td< td=""><td>499</td><td></td><td>-4.08</td><td>SCF34.18</td><td></td></td<>	499		-4.08	SCF34.18	
2077-1.220.55 $div1/A/SC4A10.10c$ $Div1/A$ $Div1A$ $'$ 2084-2.100.74 $murG/SC4A10.17c$ $putative UDP-N-actylglucosamine-N-a$					
2084-2.100.74mcrG/SCA10.17cputtive UDP-N-scetylglucosamine V-scetylglucosamine V-scetylglucos					
2049 $-240$ $0/4$ $minU/2cm$ $prophosphoryLandecaprenol N-acetylglucosaminetransferzas MurG24311.15-0.88dylA/SCC24/02AbfA24550.980.31mirA/SC7A8/04RNA polymerase principal sigm factor HrldAactH/SCC105.1027911.860.99acHI/SCC105.10putative scretted protein/Deserritoxaminesputative scretted protein/Deserritoxamines2781-1.12-1.70SCC105.11putative scretted protein/Deserritoxaminesputative scretted protein/Deserritoxamines2782-0.47-3.94SCC105.14putative anonoxygeness / Deserritoxamines2783-0.454.20SCC105.16conserved hypothesia/Deserritoxamines2784-0.464.20SCC105.16conserved hypothesia/Deserritoxamines2785-1.294.54SCC105.16conserved hypothesia/Deserritoxamines2784-2.33-2.27SCH1.19cprotein3110-2.88-5.29SCE15.16conserved hypothesia/Deserritoxamines2826-2.23-2.27int/D/SCE22.19cputative integral membraneprotein AbeA28370.86-0.71SCE15.05putative integral membraneprotein AbeA2848722-1.63SCE15.07putative integral membrane protein AbeA2849577-1.64SCE15.07putative integral membrane protein AbeC2849577-1.64SCE15.07putative enditive protein AbeB2849572-1.65$					putative UDP-N-acetylglucosamine-N-
24111.15-0.88 $dp/A/SC24.02c$ AbfA24650.980.31 $nh/A/SC7A.804c$ RNA polymerase principal sigma factor HrdA27791.860.99 $acH/SC015.10$ putative secreted protein/Desferritoxamines2780-1.12-1.70SCC105.11putative secreted protein/Desferritoxamines2781-1.12-1.70SCC105.12putative secreted protein/Desferritoxamines2782-0.07-3.94SCC105.13putative monoxygenes/Desferritoxamines2783-0.45-4.20SCC105.14putative monoxygenes/Desferritoxamines2784-0.61-4.81SCC105.15conserved nyrothetical protein/Desferritoxamines2785-1.23-4.54SCC105.16conserved nyrothetical protein/Desferritoxamines3110-2.88-5.29SCL41.19cputative accyltranterse/Desferritoxamines32870.86-0.71SCE15.04putative ABC transport system Integral membrane32887.22-1.63SCE15.05putative integral membrane protein AbeA3290807-1.80SCE15.07putative integral membrane protein AbeA32910.391.53SCE15.07putative membrane protein AbeA SARP3292-2.021.16SCE8.20putative membrane protein AbeA SARP32933.841.28ijjA/SCE2.19putative membrane protein AbeA SARP3294-2.45-0.08SCE15.07putative membrane protein AbeA3295-1.471.11gcG67.13putative membra	2084	-2.10	0.74	murG/SC4A10.17c	pyrophosphoryl-undecaprenol N-acetylglucosamine
2791860.99 $adH/SC105.10$ $acyl-Col A dehydrógenasé AcdH2780-1.17-2.95SCC105.11putative secréed protein/Desferrioxamines2781-1.12-1.70SCC105.12putative secréed protein/Desferrioxamines2782-0.07-3.94SCC105.13putative print/acal-dependent2783-0.45-4.20SCC105.14putative noncoxygenase/Desferrioxamines2784-0.61-4.43SCC105.15putative noncoxygenase/Desferrioxamines2785-1.29-4.54SCC105.16conserved hypothetical protein/Desferrioxamines3110-2.88-5.29SCE41.19;putative accyltranterase/Desferrioxamines3202-2.35-2.27Int/D/SCE22.19;RNA polymerase principal signa factor HrdD3288722-1.63SCE15.05putative integral membrane protein AbeB32895.77-1.64SCE15.05putative integral membrane protein AbeB32908.07-1.80SCE15.07hypothetical protein AbeA32110.391.33SCE15.07hypothetical protein AbeB32210.391.34SCE15.07hypothetical protein AbeC3232-2.021.16SCE62.0putative integral membrane protein AbeC32410.391.33SCE15.07hypothetical protein AbeC3232-2.021.16SCE62.0putative integral membrane protein ACD3331340-2.81-0.66SCE62.12protein34433.841.28<$	2431				AbfA
2780         -1.17         -2.95         SCC105.11         putative served protein/Desferrioxamines           2781         -1.12         -1.70         SCC105.12         hypothetical protein/Desferrioxamines           2782         -0.07         -3.94         SCC105.13         deratrop/lase/Desferrioxamines           2783         -0.45         -4.20         SCC105.14         putative acyltranerse/Desferrioxamines           2784         -0.61         -4.43         SCC105.15         putative acyltranerse/Desferrioxamines           2785         -1.29         -4.53         SCC105.16         conserved hypothetical protein/Desferrioxamines           3110         -2.88         -5.29         SCE41.19c         putative acyltranesport system integral membrane           3202         -2.35         -5.27         kCE12.0c         putative serie/arginin eft protein/Desferrioxamines           3287         0.86         -0.07         SCE15.04         putative acyltranesport system integral membrane           3289         5.77         -1.64         SCE15.05         putative itegral membrane protein AbeB           3291         0.39         1.33         SCE15.07         putative regulary protein AbeR SARP           3222         -2.02         1.16         SCE68.20         putative exerted protein     <					
2781-1.12-1.70SCC 105 12hypothetical protein/Desferritoxamines2782-0.07-3.94SCC 105 13putative pyridoxal-dependent2783-0.45-4.20SCC 105 13putative pyridoxal-dependent2784-0.61-4.481SCC 105 15putative noncovygenas/Desferritoxamines2785-1.29-4.54SCC 105 16conserved hypothetical protein/Desferritoxamines3110-2.88-5.29SCE 41.19;putative acceptitation protein/Desferritoxamines3111-4.47-5.37SCE 41.20;putative ABC transport system ATP-binding protein3202-2.35-2.27Intal/SCE 21.92;putative ABC transport system ATP-binding protein32370.86-0.71SCE 15.05putative integral membrane protein Abc3288722-1.63SCE 15.05putative integral membrane protein Abc32908.07-1.80SCE 15.05putative integral membrane protein Abc32110.391.53SCE 15.06putative integral membrane protein Abc3222-2.021.16SCE 82.0putative integral membrane protein Abc3233300-2.81SCE 15.06putative integral membrane protein Abc324133811.281.16SCE 82.0putative membrane protein Abc3258-2.280.90SCH 5.21putative integral membrane protein3666-2.18-0.34SCE 15.06putative integral membrane protein3759-2.45-0.06SCH 82.27					
2782 $-0.07$ $-3.94$ SCC105.15decarboxylase/Desferitoxamines $2783$ $-0.45$ $-4.20$ SCC105.14putative monoxygenase/Desferitoxamines $2784$ $-0.61$ $-4.81$ SCC105.15putative accyltranferase/Desferitoxamines $2785$ $-1.29$ $-4.54$ SCC105.16conserved hypothetical protein/Desferitoxamines $3110$ $-2.88$ $-5.29$ SCE41.19cputative accyltranferase/Desferitoxamines $3111$ $-4.77$ $-5.37$ SCE41.20cputative accyltranferase/Desferitoxamines $3202$ $-2.35$ $-2.27$ intd//SCE22.19cputative accyltranferase principal signa factor HrdD $3288$ $222$ $-1.63$ SCE15.05putative integral membrane protein AbeB $3290$ $577$ $-1.64$ SCE15.07hypothetical protein AbeD $3291$ $0.39$ $1.53$ SCE15.07hypothetical protein AbeD $3232$ $-2.02$ $1.66$ SCE15.07putative integral membrane protein AbeA $3323$ $394$ $2.28$ $577$ $-1.64$ $3288$ $-2.02$ $1.66$ SCE15.07putative morbian AbeD $3290$ $8.07$ $-1.80$ SCE15.07putative morbian abed D $3323$ $394$ $2.28$ $576$ putative accyltranker regulator TipA $3413$ $381$ $1.28$ $474$ /SCE9.20putative codoreductase $3558$ $-2.38$ $0.90$ SCH5.21putative codoreductase $3607$ $-2.45$ $-0.08$ SCH5.22putative codoreductase <td>2781</td> <td>-1.12</td> <td>-1.70</td> <td></td> <td>hypothetical protein/Desferrioxamines</td>	2781	-1.12	-1.70		hypothetical protein/Desferrioxamines
2783-0.45-4.20SCC 105 15putative moneoxygenase/Desferioxamines2784-0.61-4.81SCC 105 15conserved hypothetical protein/Desferioxamines2785-1.29-4.54SCC 105 16conserved hypothetical protein/Desferioxamines3110-2.88-5.29SCE41.19cputative ABC transport system integral membrane3111-4.77-5.37SCE41.20cputative ABC transport system ATP-binding protein3122-2.35-2.27hrdD/SCE22.19cRNA polymerase principal sigma factor HrdD22887.22-1.63SCE15.05putative altergal membrane protein AbeA32995.77-1.64SCE15.07pypothetical protein AbeC32910.391.53SCE15.07putative regulatory protein a SCO358 homolog3323390251SCE8.20putative regulatory protein a SCO358 homolog3323390251SCE8.21putative membrane protein AbeC3558-2.380.90SCH5.21putative enerbrane protein3608-3.18-0.34SC6673.18cputative enerbrane protein3608-3.18-0.34SC6673.18chydothetical protein36090.400.40SCB4C20F6.12putative exidered RNA polymerase beta chain RpoB36770.52255SCDDNA-directed RNA polymerase beta chain RpoB36760.66SCB4C20F6.12putative exidered transportein/Actinorhodin37741.471.11rpc//SCD82.2637840.66SCB4C20F6	2782	-0.07	-3.94	SCC105.13	
278-1.29-4.54SCC 105.16conserved hypothetical protein/Desferrioxamines3110-2.88-5.29SCE41.19cputative ABC transport system integral membrane3111-4.77-5.37SCE41.20cputative ABC transport system ATP-binding protein3202-2.35-2.27hrdD/SCE2.19cRNA polymerase principal signa factor HrdD3288Z22-1.64SCE15.05putative serie/arginine rich protein AbcA32995.77-1.64SCE15.05putative integral membrane protein AbcB32910.391.33SCE15.07hypothetical protein AbcB32110.391.53SCE15.07putative integral membrane protein AbcC32202.021.16SCE8.2.0putative membrane protein AbcB3322-2.021.16SCE8.2.0putative membrane protein AbcB33233.902.51SCE68.2.1putative membrane protein AbcA3358-2.380.90SCH5.21putative integral membrane protein3607-2.45-0.08SCH5.22putative integral membrane protein3608-3.18-0.34SC6673.18chypothetical protein3608-3.18-0.34SC6673.19chypothetical protein36770.66SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.12putative oxidoreductase/Actinorhodin50711.747.99SCBAC20F6.12putative oxidoreductase/Actinorhodin50730.922.03	2783	-0.45	-4.20	SCC105.14	
3110 $-2.88$ $-5.29$ SCE41.19cputative ABC transport system integral membrane protein $3111$ $-4.77$ $-5.37$ SCE41.20cputative ABC transport system ATP-binding protein $3202$ $-2.35$ $-2.27$ $lnrdD/SCE22.19c$ RNA polymerase principal sigma factor HrdD $3287$ $0.86$ $-0.71$ SCE15.04putative integral membrane protein AbeA $3288$ $7.22$ $-1.63$ SCE15.05putative integral membrane protein AbeA $3289$ $5.77$ $-1.64$ SCE15.06putative integral membrane protein AbeC $3290$ $807$ $-1.80$ SCE15.08putative membrane protein AbeB SARP $3222$ $-2.02$ $1.16$ SCE68.20putative membrane sigma factor BIdN $3323$ $390$ $2.51$ SCE68.21putative morphological differentiation-associated $3359$ $-2.38$ $0.90$ SCH5.21putative morphological differentiation-associated $3607$ $-2.45$ $-0.08$ SCH5.21putative sciented protein $3608$ $-3.18$ $-0.24$ SC6673.19cputative oxidoreductase $3609$ $0.40$ $0.40$ SCBAC20F6.12putative oxidoreductase/Actinorhodin $3609$ $0.40$ $0.40$ SCBAC20F6.12putative oxidoreductase/Actinorhodin $3609$ $0.40$ $0.40$ SCBAC20F6.13hydroxylacyl-CoA dehydrogenase/Actinorhodin $5070$ $0.87$ $0.66$ SCBAC20F6.14hydroxylacyl-CoA dehydrogenase/Actinorhodin $5071$ $1.92$ $2.55$ SCBAC20F6.15h					
110-2.55-0.27SC.P4.19c proteinprotein1.10.1 <th0.1< th="">0.10.10.10.1</th0.1<>					
3202 $-2.35$ $-2.27$ Intd/SC22.19cKNA polymerase principal sigma factor HdD $3287$ $0.86$ $-0.71$ SCEI5.04putative series / arginine rich protein AbeA $3288$ $722$ $-1.64$ SCEI5.05putative integral membrane protein AbeB $3290$ $807$ $-1.64$ SCEI5.06putative integral membrane protein AbeB $3290$ $0.39$ $-1.80$ SCEI5.07hypothetical protein AbeB $3222$ $-2.02$ $1.16$ SCE68.20putative regulatory protein AbeR SARP $3322$ $-2.02$ $1.16$ SCE68.21putative regulatory protein AbeR SARP $3323$ $390$ $251$ SCE68.21putative regulator TpA $3413$ $381$ $1.28$ SCH5.21putative environe protein, $3CO358$ homolog $3558$ $-2.38$ $0.90$ SCH5.21putative oxidoreductase $3607$ $-2.72$ $-1.51$ SC6673.19chypothetical protein $3608$ $-3.18$ $-0.34$ SC6673.19chypothetical protein $4654$ $-1.57$ $1.74$ $7pO/SCD82.26$ DNA-directed RNA polymerase beta chain RpoB $4655$ $-1.47$ $1.11$ $7pO/SCD82.27$ SCDDNA-directed RNA polymerase beta chain RpoB $5070$ $0.87$ $0.66$ SCBAC20F6.12putative oxidoreductase/Actinorhodin $5072$ $1.34$ $1.99$ SCBAC20F6.13hydroxylacyl-CoA dehydrogenase/Actinorhodin $5073$ $0.74$ $2.12$ SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin $5076$ $0.67$ <					protein
32870.86 $-0.71$ SCE15.04putative serine/arginue ind/protein AbeA32887.22 $-1.63$ SCE15.05putative integral membrane protein AbeB32895.77 $-1.64$ SCE15.05putative integral membrane protein AbeC32908.07 $-1.80$ SCE15.07hypothetical protein AbeB3221 $-2.02$ 1.16SCE68.20putative membrane protein, a SCO3558 homolog33233002.51SCE68.21putative membrane protein, a SCO3558 homolog34133811.28tipA/SCE9.20transcriptional regulatory protein3559 $-2.45$ $-0.08$ SCH5.21protein3607 $-2.72$ $-1.51$ SC6673.18putative exidoreductase3608 $-3.18$ $-0.34$ SC6173.19hypothetical protein36090.400.40SCBAC20F6.12putative exidoreductase50690.400.40SCBAC20F6.12putative exidoreductase/Actinorhodin50711.92255SCBAC20F6.16hydroxlacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16hydroxlacyl-CoA dehydrogenase/Actinorhodin50741.671.83SCBAC20F6.16hydroxlacyl-CoA dehydrogenase/Actinorhodin50750.922.07 $0.74/SCBAC28C1.01$ putative exidoreductase/Actinorhodin50760.670.24 $atVA1/SCBAC28C1.01$ putative exidoreductase/Actinorhodin50750.922.07 $0.74/SCBAC28C1.01$ putative exidoreductase/Actinorhodin					
32887.22-1.63SCE 15.05putative integral membrane protein AbeB32895.77-1.80SCE 15.06putative integral membrane protein AbeB32908.07-1.80SCE 15.06putative regulatory protein AbeB ASAR32910.391.53SCE 15.08putative regulatory protein AbeB SARP3322-2.021.16SCE 68.20putative membrane protein abeC33233902.51SCE 68.21putative membrane protein abeC34133811.28tip A/SCE 9.20putative morphological differentiation-associated3558-2.380.90SCH 5.22putative screted protein3608-3.18-0.03SCG 51.316putative screted protein3608-3.18-0.34SCG 673.19chypothetical protein4654-1.571.74rpoB/SCD 82.26DNA-directed RNA polymerase beta chain RpoB50700.400.40SCB AC20F6.12putative oxidoreductase/Actinorhodin50711.922.55SCB AC20F6.12putative oxidoreductase/Actinorhodin50721.341.99SCB AC20F6.16putative oxidoreductase/Actinorhodin50730.742.12SCB AC20F6.16putative dehydragenase/Actinorhodin50750.922.07ORF4/SCB AC28C1.01putative dehydragenase/Actinorhodin50750.922.07ORF4/SCB AC28C1.01putative dehydragenase/Actinorhodin50760.670.24actWA/SCB AC28C1.01putative dehydragenase/Actinorhodin <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<>					
3290807-1.80SCE15.07hypothetical protein AbeD32910.391.53SCE15.08putative regulatory protein AbeR SARP3222-2.021.16SCE68.20putative rembrane protein, a SC03558 homolog33233902.51SCE68.21putative RNA polymerase sigma factor BldN34133811.28 $iipA/SCE9.20$ transcriptional regulator TipA3558-2.380.90SCH5.21putative morphological differentiation-associated protein3559-2.45-0.08SCH5.22putative secreted protein3608-3.18-0.34SC6673.18cputative secreted protein4654-1.571.74 $rpol/SCD82.26$ DNA-directed RNA polymerase beta chain RpoB4655-1.471.11 $rpoC/SCD82.27$ RpoC50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50711.922.55SCBAC20F6.12putative oxidoreductase/Actinorhodin50730.742.12SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50741.671.83SCBAC20F6.16hydroxylacy/AcA dehydrogenase/Actinorhodin50750.922.070.074/3/SCBAC28G1integral membrane protein/Actinorhodin50760.670.24actWAJ/SCBAC28G1hypothetical protein/Actinorhodin50781.650.86actWAJ/SCBAC28G1hypothetical protein/Actinorhodin50760.670.24actWAJ/SCBAC28G1hypothetical protein/Actinorhodin<					
32910.391.53SCE 15.08putative regulatory protein AbeR SARP3322-2.021.16SCE 68.20putative rembrane protein, a SCO 3558 homolog33233902.51SCE 68.21putative membrane protein, a SCO 3558 homolog34133811.28tip/A/SCE 9.20transcriptional regulator TipA3558-2.380.90SCH 5.21putative morphological differentiation-associated3559-2.45-0.08SCH 5.22putative screted protein3607-2.72-1.51SC 6673.18chypothetical protein3608-3.18-0.34SC 6673.19chypothetical protein3608-1.571.74rpol/SCD 82.26DNA-directed RNA polymerase beta chain RpoB36070.400.40SCB AC2076.12putative oxidoreductase/4655-1.471.11rpol/SCD 82.27RpoC50690.400.40SCB AC2076.12putative oxidoreductase/ Actinorhodin50711.92 <b>2.55</b> SCB AC2076.12putative oxidoreductase/ Actinorhodin50730.742.12SCB AC2076.16hydroxylacyl-CoA dehydrogenase/ Actinorhodin50750.922.07ORF4/SCB AC2861iputative oxidoreductase/ Actinorhodin50760.670.24artWal/SCB AC2861hypothetical protein/ Actinorhodin50792.620.31artWal/SCB AC2861hypothetical protein/ Actinorhodin50750.922.07ORF4/SCB AC2861hypothetical protein/ Actinorhodin5076					
32233.902.51SCE68.21putative RNA polymerase sigma factor BldN34133.811.28tipA/SCE9.20transcriptional regulator TipA3558-2.380.90SCH5.21putative morphological differentiation-associated3559-2.45-0.08SCH5.22putative oxidoreductase3607-2.72-1.51SC6613.18cputative excited protein3608-3.18-0.34SC6573.19chypothetical protein3609-1.471.11 $rpoC/SCD82.26$ DNA-directed RNA polymerase beta chain RpoB4655-1.471.11 $rpoC/SCD82.27$ SCDDNA-directed RNA polymerase beta chain RpoB50700.870.66SCBAC20F6.12putative oxidoreductase/Actinorhodin50711.922.55SCBAC20F6.13hydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.16hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.17putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC2861.10$ putative oxidoreductase/Actinorhodin5077-0.091.19 $artVA1/SCBAC2861hypothetical protein/Actinorhodin50781.650.86artVA3/SCBAC2861hypothetical protein/Actinorhodin50781.650.86artVA3/SCBAC2861hypothetical protein/Actinorhodin50781.650.86artVA3/SCBAC2861hypothetical protein/Actinorhodin50810.482.40artVA3/SCBAC2861hypothetica$					
34133.811.28 $tipA/SCE9.20$ transcriptional regulator TipÅ3558-2.380.90SCH5.21putative morphological differentiation-associated3559-2.45-0.08SCH5.22putative oxidoreductase3607-2.72-1.51SC6673.18cputative screted protein3608-3.18-0.34SC6673.19chypothetical protein4654-1.571.74 $rpoB/SCD82.26$ DNA-directed RNA polymerase beta chain RpoB4655-1.471.11 $rpoC/SCD82.27$ RpoC50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.12putative oxidoreductase/Actinorhodin50711.922.55SCBAC20F6.16hydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.16putative oxidoreductase/Actinorhodin50741.671.83SCBAC20F6.16putative oxidoreductase/Actinorhodin50750.922.07 $oRF4/SCBAC28G1$ putative oxidoreductase/Actinorhodin5077-0.091.19 $artVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $artVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $artVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $artVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $artVA3/SCBAC28G1$ hypothetical protein/Actinorhodin5079 </td <td></td> <td></td> <td></td> <td></td> <td></td>					
3558-2.380.90SCH5.21putative morphological differentiation-associated protein3559-2.45-0.08SCH5.22cputative oxidoreductase3607-2.72-1.51SC6613.18cputative oxidoreductase3608-3.18-0.34SC6613.19chypothetical protein3608-1.571.74rp08/SCD82.26DNA-directed RNA polymerase beta chain RpoB4654-1.571.74rp08/SCD82.26DNA-directed RNA polymerase beta chain RpoB4655-1.471.11rp0C/SCD82.27RpoC50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.13chydroxylacyl-CoA dehydrogenase/Actinorhodin50711.922.55SCBAC20F6.16putative oxidoreductase/Actinorhodin50721.341.99SCBAC20F6.17putative exidoreductase/Actinorhodin50730.742.12SCBAC20F6.17putative exidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1$ integral membrane protein/Actinorhodin5077-0.091.19actVA3/SCBAC28G1integral membrane protein/Actinorhodin50781.650.86actWA3/SCBAC28G1pypothetical protein/Actinorhodin50801.25-0.41actWA5/SCBAC28G1putative hydrolase/Actinorhodin50810.482.40actWA5/SCBAC28G1pypothetical protein/Actinorhodin5083-0.12-2.64actII-1/SCBAC28G1putative ensorptional regulatory <td></td> <td></td> <td></td> <td></td> <td></td>					
protein3559-2.45-0.08SCH5.22putative oxidoreductase3607-2.72-1.51SC66T3.18cputative secreted protein3608-3.18-0.34SC66T3.19chypothetical protein4654-1.571.74 $rpoB/SCD82.26$ DNA-directed RNA polymerase beta chain RpoB4655-1.471.11 $rpoC/SCD82.27$ SCDDNA-directed RNA polymerase beta 'chain50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.12putative oxidoreductase/Actinorhodin50711.922.55SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1.01$ putative oxidoreductase/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA3/SCBAC28G1$ putative hydrolase/Actinorhodin50810.482.40 $actVA3/SCBAC28G1$ putative hydrolase/Actinorhodin5083-0.12-2.64 $actII-1/SCBAC28G1$ putative membrane protein/Actinorhodin5083-0.12-2.64 $actII-3/SCBAC28G1$ putative membrane protein/Actinorhodin					1 0 1
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					*
4654-1.571.74 $rpoB/SCD82.26$ DNA-directed RNA polymerase beta chain RpoB4655-1.471.11 $rpoC/SCD82.27$ SCDDNA-directed RNA polymerase beta' chain50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.13chydroxylacyl-CoA dehydrogenase/Actinorhodin50711.92 <b>2.55</b> SCBAC20F6.15chydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1.01$ putative oxidoreductase/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ integral membrane protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA4/SCBAC28G1$ putative dyrohase/Actinorhodin50810.482.40 $actVA6/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5082-1.180.42 $actII-1/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64 $actII-2/SCBAC28G1$ putative membrane protein/Actinorhodin					putative secreted protein
4655-1.471.11 $r_{pC}/SCD82.27$ SCDDNA-directed RNA polymerase beta' chain RpoC50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.13chydroxylacyl-CoA dehydrogenase/Actinorhodin50711.922.55SCBAC20F6.14chydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50741.671.83SCBAC20F6.17putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1$ integral membrane protein/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50801.25-0.41 $actVA5/SCBAC28G1$ putative hypothetical protein/Actinorhodin50810.482.40 $actII-1/SCBAC28G1$ putative transcriptional regulatory5083-0.12-2.64 $actII-3/SCBAC28G1$ putative transcriptional regulatory50841.31-3.45 $actII-3/SCBAC28G1$ putative actinorhodin					
40.01.11 $ppc/9CD02.27$ RpoC50690.400.40SCBAC20F6.12putative oxidoreductase/Actinorhodin50700.870.66SCBAC20F6.13chydroxylacyl-CoA dehydrogenase/Actinorhodin50711.922.55SCBAC20F6.14chydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1.01$ putative oxidoreductase/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ integral membrane protein/Actinorhodin50781.650.86 $actVA2/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA4/SCBAC28G1$ putative hypothesical protein/Actinorhodin50801.25 $-0.41$ $actVA6/SCBAC28G1$ hypothetical protein/Actinorhodin50810.482.40 $actVA6/SCBAC28G1$ hypothetical protein/Actinorhodin5082 $-1.18$ 0.42 $actII-1/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5083 $-0.12$ $-2.64$ $actII-2/SCBAC28G1$ putative atmorbodin50841.31 $-3.45$ $actII-3/SCBAC28G1$ putative atmorbodin					SCDDNA-directed KINA polymerase beta chain KpoB
50700.870.66SCBAC20F6.13chydroxylacyl-CoA dehydrogenase/Actinorhodin50711.92 <b>2.55</b> SCBAC20F6.14chydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50741.671.83SCBAC20F6.17putative oxidoreductase/Actinorhodin50750.922.07ORF4/SCBAC28G1.01putative oxidoreductase/Actinorhodin50760.670.24actVA1/SCBAC28G1integral membrane protein/Actinorhodin5077-0.091.19actVA2/SCBAC28G1hypothetical protein/Actinorhodin50781.650.86actVA3/SCBAC28G1conserved hypothetical protein/Actinorhodin50801.25-0.41actVA6/SCBAC28G1putative hydrolase/Actinorhodin50810.482.40actVI6/SCBAC28G1putative hydrolase/Actinorhodin5083-0.12-2.64actII-1/SCBAC28G1putative transcriptional regulatory protein/Actinorhodin50841.31-3.45actII-3/SCBAC28G1putative membrane protein/Actinorhodin					RpoC
50711.922.55SCBAC20F6.14chydroxylacyl-CoA dehydrogenase/Actinorhodin50721.341.99SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50741.671.83SCBAC20F6.17putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1.01$ putative oxidoreductase/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ integral membrane protein/Actinorhodin5077-0.091.19 $actVA2/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA5/SCBAC28G1$ putative hydrolase/Actinorhodin50810.482.40 $actVA6/SCBAC28G1$ putative hydrolase/Actinorhodin5082-1.180.42 $actII-1/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64 $actII-2/SCBAC28G1$ putative membrane protein/Actinorhodin50841.31-3.45 $actII-3/SCBAC28G1$ putative membrane protein/Actinorhodin					
50721.341.99SCBAC20F6.15hydroxylacyl-CoA dehydrogenase/Actinorhodin50730.742.12SCBAC20F6.16putative oxidoreductase/Actinorhodin50741.671.83SCBAC20F6.17putative oxidoreductase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1.01$ putative oxidoreductase/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ integral membrane protein/Actinorhodin5077-0.091.19 $actVA2/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA4/SCBAC28G1$ putative hydrolase/Actinorhodin50801.25-0.41 $actVA6/SCBAC28G1$ putative hydrolase/Actinorhodin50810.482.40 $actVA6/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5082-1.180.42 $actII-1/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64 $actII-3/SCBAC28G1$ putative membrane protein/Actinorhodin50841.31-3.45 $actII-3/SCBAC28G1$ putative membrane protein/Actinorhodin					
50741.671.83SCBAC20F6.17putative dehydratase/Actinorhodin50750.922.07 $ORF4/SCBAC28G1.01$ putative oxidoreductase/Actinorhodin50760.670.24 $actVA1/SCBAC28G1$ integral membrane protein/Actinorhodin5077-0.091.19 $actVA2/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA4/SCBAC28G1$ conserved hypothetical protein/Actinorhodin50801.25-0.41 $actVA5/SCBAC28G1$ putative hydrolase/Actinorhodin50810.482.40 $actVA6/SCBAC28G1$ hypothetical protein/Actinorhodin5082-1.180.42 $actII-1/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64 $actII-2/SCBAC28G1$ putative actinorhodin transporter/Actinorhodin50841.31-3.45 $actII-3/SCBAC28G1$ putative membrane protein/Actinorhodin	5072	1.34	1.99	SCBAC20F6.15	hydroxylacyl-CoA dehydrogenase/Actinorhodin
50750.922.07ORF4/SCBAC28G1.01putative oxidoreductase/Actinorhodin50760.670.24actVA1/SCBAC28G1integral membrane protein/Actinorhodin5077-0.091.19actVA2/SCBAC28G1hypothetical protein/Actinorhodin50781.650.86actVA3/SCBAC28G1hypothetical protein/Actinorhodin50792.620.31actVA4/SCBAC28G1conserved hypothetical protein/Actinorhodin50801.25-0.41actVA5/SCBAC28G1putative hydrolase/Actinorhodin50810.482.40actVA6/SCBAC28G1hypothetical protein/Actinorhodin5082-1.180.42actII-1/SCBAC28G1putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64actII-2/SCBAC28G1putative membrane protein/Actinorhodin50841.31-3.45actII-3/SCBAC28G1putative membrane protein/Actinorhodin					
50760.670.24 $actVA1/SCBAC28G1$ integral membrane protein/Actinorhodin5077 $-0.09$ 1.19 $actVA2/SCBAC28G1$ hypothetical protein/Actinorhodin50781.650.86 $actVA3/SCBAC28G1$ hypothetical protein/Actinorhodin50792.620.31 $actVA4/SCBAC28G1$ putative hydrolase/Actinorhodin50801.25 $-0.41$ $actVA6/SCBAC28G1$ putative hydrolase/Actinorhodin50810.482.40 $actVA6/SCBAC28G1$ hypothetical protein/Actinorhodin5082 $-1.18$ 0.42 $actII-1/SCBAC28G1$ putative transcriptional regulatory protein/Actinorhodin5083 $-0.12$ $-2.64$ $actII-2/SCBAC28G1$ putative actinorhodin transporter/Actinorhodin50841.31 $-3.45$ $actII-3/SCBAC28G1$ putative membrane protein/Actinorhodin					
50781.650.86actVA3/SCBAC28G1hypothetical protein/Actinorhodin50792.620.31actVA4/SCBAC28G1conserved hypothetical protein/Actinorhodin50801.25-0.41actVA5/SCBAC28G1putative hydrolase/Actinorhodin50810.482.40actVA6/SCBAC28G1hypothetical protein/Actinorhodin5082-1.180.42actII-1/SCBAC28G1putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64actII-2/SCBAC28G1putative actinorhodin transporter/Actinorhodin50841.31-3.45actII-3/SCBAC28G1putative membrane protein/Actinorhodin	5076	0.67	0.24	actVA1/SCBAC28G1	integral membrane protein/Actinorhodin
50792.620.31actVA4/SCBAC28G1 actVA5/SCBAC28G1conserved hypothetical protein/Actinorhodin50801.25-0.41actVA5/SCBAC28G1 actVA5/SCBAC28G1putative hydrolase/Actinorhodin50810.482.40actVA6/SCBAC28G1 actVA6/SCBAC28G1hypothetical protein/Actinorhodin5082-1.180.42actII-1/SCBAC28G1 protein/Actinorhodinputative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64 -3.45actII-2/SCBAC28G1 actII-3/SCBAC28G1putative actinorhodin transporter/Actinorhodin					
50801.25-0.41actVA5/SCBAC28G1putative hydrolase/Actinorhodin50810.482.40actVA6/SCBAC28G1hypothetical protein/Actinorhodin5082-1.180.42actII-1/SCBAC28G1putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64actII-2/SCBAC28G1putative actinorhodin transporter/Actinorhodin50841.31-3.45actII-3/SCBAC28G1putative membrane protein/Actinorhodin					
5082-1.180.42actII-1/SCBAC28G1putative transcriptional regulatory protein/Actinorhodin5083-0.12-2.64actII-2/SCBAC28G1putative actinorhodin transporter/Actinorhodin50841.31-3.45actII-3/SCBAC28G1putative membrane protein/Actinorhodin	5080	1.25	-0.41	actVA5/SCBAC28G1	putative hydrolase/Actinorhodin
5082-1.180.42actII-1/SCBAC28G1protein/Actinorhodin5083-0.12-2.64actII-2/SCBAC28G1putative actinorhodin transporter/Actinorhodin50841.31-3.45actII-3/SCBAC28G1putative membrane protein/Actinorhodin					
5084     1.31     -3.45     actII-3/SCBAC28G1     putative membrane protein/Actinorhodin			0.42		protein/Actinorhodin
	5084 5085	-0.82	-3.45 5.01	actII-3/SCBAC28G1 actII-4/SCBAC28G1	actinorhodin cluster activator protein/Actinorhodin

# Table 2. Cont.

Gene SCO Number	Average Differential Expression (C6S/C0)		— Gene/Cosmid Name	Protein/Gene Cluster
	Young Cells (72 h)	Old Cells (144 h)	Gene/Cosmid Name	r rotein/Gene Cluster
5086	0.64	2.27	actIII/SCBAC28G1	ketoacyl reductase/Actinorhodin
5087	0.76	1.90	actI-1/SCBAC28G	actinorhodin polyketide beta-ketoacyl synthaselph subunit/Actinorhodin
5088	0.90	0.84	actI-2/SCBAC28G	actinorhodin polyketide beta-ketoacyl synthaseeta subunit/Actinorhodin
5089	0.67	2.72	actI-3/SCBAC28G	actinorhodin polyketide synthase acyl carrierprotein/Actinorhodin
5090	0.02	2.27	actVII/SCBAC28G1	actinorhodin polyketide synthase bifunctionalyclase/dehydratase/Actinorhodin
5091	-0.07	1.54	actIV/SCBAC28G1.1	cyclase/Actinorhodin
5092	0.61	0.80	actVB/SCBAC28G1.1	actinorhodin polyketide putative dimerase/Actinorhodin
5572	-3.99	2.24	rnc/SC7A1.16	ribonuclease III/RNase III
5621	-1.70	3.75	whiG/SC2E1.38	RNA polymerase sigma factor WhiG
5819	1.33	1.96	whiH	Sporulation transcription factor WhiH
5820	-0.49	1.97	hrdB/SC5B8.10	major vegetative sigma factor HrdB
5877	1.96	3.21	redD	transcriptional regulator RedD/Prodiginines
5878	1.34	0.94	redX	polyketide synthase RedX/Prodiginines
5879	0.33	0.32	redW	acyl-coa dehydrogenase RedW/Prodiginines
5880	0.09	3.34	redY	RedY protein/Prodiginines
881	-1.54	2.78	redZ	response regulator/Prodiginines
882	0.61	0.02	redV/SC3F7.02c	Prodiginines
883	0.79	0.87	redU/SC3F7.03c	Prodiginines
884	1.41	0.09	SC3F7.04c	hypothetical protein/Prodiginines
885	1.21	-0.66	SC3F7.05c	hypothetical protein/Prodiginines
5886	1.68	2.31	redR/SC3F7.06c	Prodiginines
887	2.60	0.20	redQ/SC3F7.07c	Prodiginines
888	0.94	-0.50	redP/SC3F7.08	3-oxoacyl-[acyl-carrier-protein] synthase/Prodiginines
889	2.70	0.50	redO/SC3F7.09	hypothetical protein/Prodiginines
5890	1.65	0.89	redN/SC3F7.10	putative 8-amino-7-oxononanoate synthase/Prodiginines
5891	1.02	-0.79	redM/St3F7.11	putative peptide synthase/Prodiginines
892	0.92	-0.28	redL/SC3F7.12	polyketide synthase/Prodiginines
5893	0.82	0.08	redK/SC3F7.13	oxidoreductase/Prodiginines
5894	0.69	0.02	redJ/SC3F7.14	thioesterase/Prodiginines
5895	1.24	-0.04	redI/SC3F7.15	putative methyltransferase/Prodiginines
5896	1.45	0.17	SC10A5.01	phosphoenolpyruvate-utilizing enzyme/Prodiginines
5897	2.47	0.76	redG/SC10A5.02	Prodiginines
5898	2.38	1.57	redF/SC10A5.03	Prodiginines
5265	-0.25	0.51	scbR/SCAH10.30c	Gamma-butyrolactone binding protein
5266	1.63	1.14	scbA/SCAH10.31	SCB1 butanolide synthase, an AfsA homolog/Gamma-butyrolactone
6267	-0.44	1.19	SCAH10.32	hypothetical protein, a BprA homolog
5992	1.82	5.48	absR1/SC8F11.18c	regulatory protein AbsR1
5993	1.31	2.10	absR2/SC8F11.19	regulatory protein AbsR2
7221	-0.75	3.04	SC2H12.20c	Gcs type III polyketide synthase
-2.5	-1.5 -(	0.8 -0.2	0.2 0.8	1.5 2.5

#### Table 2. Cont.

# 4. Discussion

The regulatory capabilities of small RNAs have only been appreciated for the last 20 years or so. This lack of awareness is exemplified in work by Nishiyama et al. [31], where the authors created a *Streptomyces azureus* strain that overexpressed the BalA1 region of the chromosome (a 2.5-kb chromosomal DNA fragment). The resulting BalA1 strain formed little aerial hyphae and exhibited a capacity to overproduce secondary metabolites. The authors focused on the fact that the equivalent chromosomal region in the *S. coelicolor* genome contains two protein-coding genes: *SCO3557* and *SCO3558*. They referred to *SCO3558* as encoding a "morphological differentiation-associated protein". Subsequent work [14,24,32] has revealed, however, that the *SCO3558* gene is flanked by two sRNA-coding genes *scr3558* (encoding 6C RNA) [24,33] and by the scr3559 (investigated here) (Figure 1). Expression of both scr3558 and scr3559 RNAs has been verified. Mutagenesis of the *scr3558* gene had no effect on cell physiology (personal communication [34]), whereas deletion [16] and/or overproduction of the scr3559 RNA (our C6S strain) led to changes in morphological development and secondary metabolite production. The phenotypes in this study are reminiscent of those described for the *S. azureus* BalA1 strain, where the

13 of 18

scr3559-equivalent RNA could be responsible for the observed change in cell physiology following overexpression of the sRNA region.

One may speculate that the BalA1 phenotype could be caused by increased expression of other gene product(s) from the BalA1 locus, including SCO3558 or SCO3559. The *SCO3558* gene is a possible paralogue of the *mmfP* gene, which is located in a cluster of genes encoding enzymes responsible for the synthesis of the methylenomycin furans (MMFs) from the SCP1 plasmid of *S. coelicolor* [35]. These MMFs are freely diffusible signaling molecules that control the expression of the plasmid-encoded antibiotic methylenomycin. Nishiyama et al. also demonstrated that the *S. azureus* BalA1 strain induced its neighboring *S. coelicolor* A3(2) to produce the red antibiotic undecylprodigiosin early on in its life cycle. We therefore speculated that the scr3559 RNA in *S. coelicolor* may also contribute to the control of signaling molecule(s). However, we did not see any influence of the C6S strain on the development of the neighboring C0 strain, as was observed in the BalA1 strain. It is not yet clear whether either of the flanking protein-coding genes (*SCO3558* and *SCO3559*), contribute to *Streptomyces* development, as their expression decreased in the C6S strain according to our microarray data.

The results presented here indicate that sRNAs contribute to the control of antibiotic production in *Streptomyces* species. Several pioneering studies on specific small RNAs expressed in *Streptomyces* have been published [36–38]. Subsequent bioinformatic approaches have predicted that tens of sRNA transcripts might be expressed during the developmental cycle of *S. coelicolor* [14,24,25,32,39,40]. The scr3559 RNA, whose pleiotropic phenotypic effects are described here, was first detected by Panek [14]. Further study revealed that the transcript's secondary structure is reminiscent of the well-characterized 6S RNA [15]. Binding assays confirmed that *scr3559* can form a complex with RNAP-HrdB and an analysis of its secondary structure validated these earlier predictions [16].

As we found here, two forms of scr3559 RNA are produced: a longer 260 nt-long molecule referred to here as pre-scr3559, and a shorter 192 nt-long "processed" form. 6S RNA processing has been studied in *E. coli* and other proteobacteria, where two precursor transcripts (transcribed from different promoters) are processed to give a mature 183 nt 6S RNA [41]. RNase E and its paralogue RNase G are required for this processing [41]. A similar situation has been noted in *Bacillus thuringiensis*, where two genes, *ssrSA* and *ssrSB*, are co-transcribed and processed by ribonucleases to give a functional 6S RNA [42]. It would be expected that equivalent RNases may contribute to the processing of the 6S RNA in *S. coelicolor* (Figure 2b); however, this has not yet been explored experimentally. It is also not known whether both precursor and processed form.

Interestingly, a deep sequencing analysis of *S. coelicolor* transcriptome detected a transcript antisense to the scr3559 RNA which is also expressed in the early stationary phase of cell development [32]. We believe that this could be a transcript equivalent to Ms1 RNA found in *Mycobacterium smegmatis* where it is positioned in the same antisense orientation [15,43]. Ms1 RNA accumulates in stationary phase and forms a 6S-like secondary structure [44]. Therefore, Ms1 RNA has been proposed to be the mycobacterial 6S RNA. It was however later demonstrated that Ms1 does not bind to the primary  $\sigma^{70}$ -factor-RNAP complex, and instead forms a complex with the RNAP core that is devoid of the sigma factor [44]. This promotes increased sigma-free core RNA polymerase levels, leading to a reservoir of RNAP in stationary phase [45]. Further research is needed in order to elucidate the roles of both the 6S-like scr3559 RNA and its antisense Ms1-like transcript.

6S RNA levels are at their maximum during stationary phase in many bacteria [46]. In *E. coli*, 6S RNA levels increase up to 11 times in stationary phase compared to exponential phase [47], and the transcript effectively sequesters the majority of  $\sigma^{70}$  and upregulates  $\sigma^{S}$  synthesis [46,48,49]. This promotes optimal cell survival, promoting sigma factor switching by the transcriptional machinery and leading to different transcriptional outcomes. This allows the bacteria to better adapt to and survive various stress conditions including

nutrient limitation, and prolongs cell viability when compared with 6S RNA-deficient strains [46].

*Bacillus subtilis* is slightly more complex, as it expresses two 6S RNAs: 6S-1 RNA and 6S-2 RNA. Whereas 6S-1 RNA exhibits a similar expression profile to the *E. coli* 6S RNA, 6S-2 RNA's expression is steady throughout the cell cycle [13,50–52]. Interestingly, 6S-1 RNA impacts the timing of sporulation [53]. A strain of *B. thuringiensis* lacking 6S-1 RNA also exhibited a reduced capacity to survive stationary phase and was defective in spore formation [42]. 6S RNA has also been observed to mediate transition into a dormant state in *Coxiella burnetii*, an obligate intracellular pathogen. The cellular level of 6S RNA in this bacterium peaks after developmental differentiation into a spore-like small cell variant [54].

These findings are all consistent with our observations in *Streptomyces*. As we have shown, scr3559 RNA levels increase during the transition into stationary phase, and culminate with onset of antibiotic production. When *scr3559* expression was induced by thiostrepton, the C6S strain was observed to promote rapid entry into stationary phase. On solid media, this resulted in the formation of very small, precociously sporulating colonies (Figure 5).

These observations correlated with our microarray analyses, where we observed increased transcript levels for genes whose products drive aerial hyphae development, septation and sporulation in the C6S strain. Although some streptomycete strains, like *S. coelicolor*, do not develop aerial mycelium and spores in liquid media, transcriptomic data suggest that gene expression in liquid and solid cultures are comparable [55]. A comparative transcriptomic study revealed that 86% of genes are expressed at the same level in both liquid and solid media, including genes involved in sporulation (*bldN, sapA*, and *whiG*, among others) [55].

The alternative BldN-sigma factor of RNAP is required for aerial mycelium formation and subsequent sporulation [56]. As our microarray data show, transcript levels of this developmental regulator in the C6S strain exhibited an almost four-fold increase in younger cells (72 h) and an approximate two and a half fold increase in older cultures (144 h) compared with the control strain C0.

Early stages of sporulation are regulated by WhiG, another alternative sigma factor of RNAP [57]. Its regulon members include *whiH*, which encodes a sporulation transcription factor [58–60]. WhiH is required for the process of aerial hyphae septation; only a few sporulation septa are formed in loosely coiled aerial hyphae when this GntR-family transcription factor is missing [58]. *whiH* also activates the expression of *geoA*, a gene encoding an enzyme responsible for the synthesis of the earthy volatile compound geosmin [61]. The expression of *whiH* and *whiG* genes was doubled and tripled, respectively, in the older C6S strain. Also upregulated in C6S was the expression of the spore-associated protein SapA-encoding gene, whose synthesis is also connected with the aerial hyphae development [62,63].

Morphological development during stationary phase is accompanied by increased secondary metabolism; this was even more active when high levels of scr3559 RNA were produced. One explanation for this could be through elevated levels of the  $\gamma$ -butyrolactone bacterial hormones. These molecules are responsible for cell signaling, coordinating morphological changes, and triggering the onset of secondary metabolism during stationary phase [64,65]. The synthesis of the *S. coelicolor* butanolide (SCB; an equivalent molecule to A-factor in *S. griseus*) is directed by the  $\gamma$ -butyrolactone synthase ScbA [66]. SCB is sensed by the receptor protein ScbR, whose repression of biosynthetic gene clusters is then relieved. Our microarray data show that in the young C6S strain, expression of *scbA* is upregulated, while expression of *scbR* is reduced. Two other genetic loci, whose expression is known to activate antibiotic production in *S. coelicolor* (the Abe cluster [67] and AbsR [68]), were also upregulated in the younger C6S strain. These activation events may contribute to the increased production of antibiotics.

Other than actinorhodin, the C6S strain produced the undecylprodigiosin (red) antibiotic earlier in its life cycle and in higher concentrations than the control C0 strain. Prodiginines are membrane damaging molecules that are produced inside the substrate mycelia cells in nutrient-deficient conditions. Lacking any self-resistance gene, they may contribute to a programmed cell death process that supports aerial hyphae development [69]. The "red" biosynthetic pathway is activated by the RedD regulator, whose gene expression is upregulated (doubled to tripled) during the development of the C6S strain. This occurs in concert with reduced growth of vegetative hyphae of the C6S strain observed here (Figure 5).

Other upregulated secondary metabolite gene clusters in the C6S strain include *crtEIBV* and *crtYTU* (in older cells), which are associated with the carotenoid isorenieratene synthesis pathway [70] and the Gcs type III polyketide (germicidins) [71], respectively. The expression of the Gcs gene *SCO7221* was tripled in older C6S cells, in accordance with the elevated germicidin levels observed in our LC-MS analysis (Figure 7). Germicidin A inhibits not only spore germination, but also vegetative hyphae elongation [72]. Thus, the germicidins may therefore contribute—possibly in association with the prodiginines—to the sporulation process supported by the scr3559 RNA.

# 5. Conclusions

The phenotypic observations presented here imply that scr3559 RNA plays a central role in the developmental control mechanisms of *Streptomyces* bacteria. The similarities shared by scr3559 RNA and bacterial 6S RNAs [16] may explain its pleiotropic effects on development and secondary metabolism. 6S RNA in *Streptomyces* may function to sequester exponential phase-specific HrdB-RNAP in order to effectively promote entry into stationary phase, leading to the formation of spores. As this development is accompanied by increased activity of secondary metabolism, the 6S RNA role also appears to include an impact on antibiotic production, given the elevated levels observed in the C6S over-expression strain.

**Author Contributions:** J.B. conceptualized the project, performed the experiments, analyzed the data, and wrote the original manuscript; A.M. performed cultivations and antibiotic production measurements; D.Š. performed northern blot experiments; M.E. assisted in the design and preparation of experiments, data interpretation, and writing the manuscript; M.Č. performed LC-MS measurements and data analyses. All of the authors proofread the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** Project No.: UJEP-SGS-2020-53-002-2 was supported by grant within student grant competition at UJEP, Jan Evangelista Purkyně University in Ústí nad Labem. This research was funded by Charles University, grant PROGRES Q25/LF1 and SVV260520, and by an NSERC Discovery grant (No. 04681) to M.E.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors are very grateful to Oldřich Benada and to Olga Kofroňová for electron microscopic pictures. We thank Karel Mikulík in memoriam for his lifelong research work and training of the next generation of scientists.

Conflicts of Interest: The authors declare no conflict of interest.

# References

- 1. Kelemen, G.H.; Buttner, M.J. Initiation of aerial mycelium formation in *Streptomyces. Curr. Opin. Microbiol.* **1998**, *1*, 656–662. [CrossRef]
- Flardh, K.; Buttner, M.J. Streptomyces morphogenetics: Dissecting differentiation in a filamentous bacterium. Nat. Rev. Microbiol. 2009, 7, 36–49. [CrossRef] [PubMed]
- Flardh, K.; Richards, D.M.; Hempel, A.M.; Howard, M.; Buttner, M.J. Regulation of apical growth and hyphal branching in Streptomyces. Curr. Opin. Microbiol. 2012, 15, 737–743. [CrossRef] [PubMed]
- 4. Bobek, J.; Strakova, E.; Zikova, A.; Vohradsky, J. Changes in activity of metabolic and regulatory pathways during germination of *S. coelicolor. BMC Genomics* **2014**, *15*, 1173. [CrossRef]

- McCormick, J.R.; Flardh, K. Signals and regulators that govern *Streptomyces* development. *FEMS Microbiol. Rev.* 2012, 36, 206–231. [CrossRef]
- 6. Hopwood, D.A. Forty years of genetics with *Streptomyces*: From in vivo through in vitro to in silico. *Microbiology* **1999**, *145 Pt 9*, 2183–2202. [CrossRef]
- Claessen, D.; de Jong, W.; Dijkhuizen, L.; Wosten, H.A. Regulation of *Streptomyces* development: Reach for the sky! *Trends Microbiol.* 2006, 14, 313–319. [CrossRef]
- Majdalani, N.; Vanderpool, C.K.; Gottesman, S. Bacterial small RNA regulators. Crit. Rev. Biochem. Mol. Biol. 2005, 40, 93–113. [CrossRef]
- 9. Wassarman, K.M. 6S RNA, a global regulator of transcription. *Microbiol. Spectr.* 2018, 6, 355–367. [CrossRef]
- Gildehaus, N.; Neusser, T.; Wurm, R.; Wagner, R. Studies on the function of the riboregulator 6S RNA from *E. coli*: RNA polymerase binding, inhibition of in vitro transcription and synthesis of RNA-directed de novo transcripts. *Nucleic Acids Res.* 2007, 35, 1885–1896. [CrossRef]
- 11. Wassarman, K.M.; Saecker, R.M. Synthesis-mediated release of a small RNA inhibitor of RNA polymerase. *Science* **2006**, *314*, 1601–1603. [CrossRef] [PubMed]
- 12. Willkomm, D.K.; Minnerup, J.; Huttenhofer, A.; Hartmann, R.K. Experimental rnomics in *aquifex aeolicus*: Identification of small non-coding RNAs and the putative 6S RNA homolog. *Nucleic Acids Res.* **2005**, *33*, 1949–1960. [CrossRef]
- 13. Barrick, J.E.; Sudarsan, N.; Weinberg, Z.; Ruzzo, W.L.; Breaker, R.R. 6S RNA is a widespread regulator of eubacterial RNA polymerase that resembles an open promoter. *RNA* **2005**, *11*, 774–784. [CrossRef]
- 14. Panek, J.; Bobek, J.; Mikulik, K.; Basler, M.; Vohradsky, J. Biocomputational prediction of small non-coding RNAs in *Streptomyces*. *BMC Genomics* **2008**, *9*, 217. [CrossRef]
- Panek, J.; Krasny, L.; Bobek, J.; Jezkova, E.; Korelusova, J.; Vohradsky, J. The suboptimal structures find the optimal RNAs: Homology search for bacterial non-coding RNAs using suboptimal RNA structures. *Nucleic Acids Res.* 2011, 39, 3418–3426. [CrossRef]
- 16. Mikulik, K.; Bobek, J.; Zidkova, J.; Felsberg, J. 6S RNA modulates growth and antibiotic production in *Streptomyces coelicolor*. *Appl. Microbiol. Biotechnol.* **2014**, *98*, 7185–7197. [CrossRef]
- 17. Sambrook, J.R.; Russell, D.W. *Molecular Cloning: A Laboratory Manual*, 3rd ed.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2001; p. A2.2.
- 18. Kieser, T.; Bibb, M.J.; Buttner, M.J.; Chater, K.F.; Hopwood, D.A. *Practical Streptomyces Genetics*, 2nd ed.; John Innes Foundation: Norwich, UK, 2000; ISBN 0-7084-0623-8.
- Shima, J.; Hesketh, A.; Okamoto, S.; Kawamoto, S.; Ochi, K. Induction of actinorhodin production by *rpsl* (encoding ribosomal protein s12) mutations that confer streptomycin resistance in *Streptomyces lividans* and *Streptomyces coelicolor* A3(2). *J. Bacteriol.* 1996, 178, 7276–7284. [CrossRef]
- 20. MacNeil, D.J.; Occi, J.L.; Gewain, K.M.; MacNeil, T.; Gibbons, P.H.; Ruby, C.L.; Danis, S.J. Complex organization of the *Streptomyces avermitilis* genes encoding the avermectin polyketide synthase. *Gene* **1992**, *115*, 119–125. [CrossRef]
- 21. Janssen, G.R.; Bibb, M.J. Derivatives of pUC18 that have BgIII sites flanking a modified multiple cloning site and that retain the ability to identify recombinant clones by visual screening of *Escherichia coli* colonies. *Gene* **1993**, *124*, 133–134. [CrossRef]
- 22. Wilkinson, C.J.; Hughes-Thomas, Z.A.; Martin, C.J.; Bohm, I.; Mironenko, T.; Deacon, M.; Wheatcroft, M.; Wirtz, G.; Staunton, J.; Leadlay, P.F. Increasing the efficiency of heterologous promoters in actinomycetes. J. Mol. Microbiol. Biotechnol. 2002, 4, 417–426.
- Redenbach, M.; Kieser, H.M.; Denapaite, D.; Eichner, A.; Cullum, J.; Kinashi, H.; Hopwood, D.A. A set of ordered cosmids and a detailed genetic and physical map for the 8 Mb *Streptomyces coelicolor* A3(2) chromosome. *Mol. Microbiol.* 1996, 21, 77–96. [CrossRef] [PubMed]
- 24. Swiercz, J.P.; Bobek, J.; Haiser, H.J.; Di Berardo, C.; Tjaden, B.; Elliot, M.A. Small non-coding RNAs in *Streptomyces coelicolor*. *Nucleic Acids Res.* **2008**, *36*, 7240–7251. [CrossRef] [PubMed]
- Setinova, D.; Smidova, K.; Pohl, P.; Music, I.; Bobek, J. RNase III-binding-mRNAs revealed novel complementary transcripts in Streptomyces. Front. Microbiol. 2017, 8, 2693. [CrossRef]
- Kang, S.G.; Jin, W.; Bibb, M.; Lee, K.J. Actinorhodin and undecylprodigiosin production in wild-type and *relA* mutant strains of Streptomyces coelicolor A3(2) grown in continuous culture. FEMS Microbiol. Lett. 1998, 168, 221–226. [CrossRef]
- 27. Cihak, M.; Kamenik, Z.; Smidova, K.; Bergman, N.; Benada, O.; Kofronova, O.; Petrickova, K.; Bobek, J. Secondary metabolites produced during the germination of *Streptomyces coelicolor*. *Front. Microbiol.* **2017**, *8*, 2495. [CrossRef]
- 28. Kamenik, Z.; Hadacek, F.; Mareckova, M.; Ulanova, D.; Kopecky, J.; Chobot, V.; Plhackova, K.; Olsovska, J. Ultra-high-performance liquid chromatography fingerprinting method for chemical screening of metabolites in cultivation broth. *J. Chromatogr. A* 2010, *1217*, 8016–8025. [CrossRef]
- 29. Gruber, A.R.; Lorenz, R.; Bernhart, S.H.; Neubock, R.; Hofacker, I.L. The Vienna RNA websuite. *Nucleic Acids Res.* 2008, 36, W70–W74. [CrossRef]
- 30. Gomez-Escribano, J.P.; Bibb, M.J. *Streptomyces coelicolor* as an expression host for heterologous gene clusters. *Methods Enzymol.* **2012**, 517, 279–300.
- Nishiyama, T.; Sakemi, H.; Sumi, H.; Tokunaga, S.; Doi, K.; Ogata, S. A chromosomal locus encoding a phosphoserine phosphataseand a truncated mind-like protein affects differentiation in *Streptomyces azureus* ATCC14921. *FEMS Microbiol. Lett.* 2000, 190, 133–139. [CrossRef]

- 32. Vockenhuber, M.P.; Sharma, C.M.; Statt, M.G.; Schmidt, D.; Xu, Z.; Dietrich, S.; Liesegang, H.; Mathews, D.H.; Suess, B. Deep sequencing-based identification of small non-coding RNAs in *Streptomyces coelicolor*. *RNA Biol.* **2011**, *8*, 468–477. [CrossRef]
- 33. Mai, J.; Rao, C.; Watt, J.; Sun, X.; Lin, C.; Zhang, L.; Liu, J. *Mycobacterium tuberculosis* 6C sRNA binds multiple mRNA targets via C-rich loops independent of RNA chaperones. *Nucleic Acids Res.* **2019**, 47, 4292–4307. [CrossRef]
- 34. Swiercz, J.P.; Elliot, M.A. McMaster University, Hamilton, ON, Canada. Unpublished work. 2009.
- 35. Corre, C.; Song, L.; O'Rourke, S.; Chater, K.F.; Challis, G.L. 2-alkyl-4-hydroxymethylfuran-3-carboxylic acids, antibiotic production inducers discovered by *Streptomyces coelicolor* genome mining. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 17510–17515. [CrossRef]
- 36. Paleckova, P.; Bobek, J.; Felsberg, J.; Mikulik, K. Activity of translation system and abundance of tmRNA during development of *Streptomyces aureofaciens* producing tetracycline. *Folia Microbiol.* **2006**, *51*, 517–524. [CrossRef]
- 37. Mikulik, K.; Paleckova, P.; Felsberg, J.; Bobek, J.; Zidkova, J.; Halada, P. SsrA genes of streptomycetes and association of proteins to the tmRNA during development and cellular differentiation. *Proteomics* **2008**, *8*, 1429–1441. [PubMed]
- 38. Engel, F.; Ossipova, E.; Jakobsson, P.J.; Vockenhuber, M.P.; Suess, B. sRNA scr5239 involved in feedback loop regulation of *Streptomyces coelicolor* central metabolism. *Front. Microbiol.* **2019**, *10*, 3121. [CrossRef]
- 39. Moody, M.J.; Young, R.A.; Jones, S.E.; Elliot, M.A. Comparative analysis of non-coding RNAs in the antibiotic-producing *Streptomyces* bacteria. *BMC Genomics* **2013**, *14*, 558. [CrossRef]
- Yi, J.S.; Kim, M.W.; Kim, M.; Jeong, Y.; Kim, E.J.; Cho, B.K.; Kim, B.G. A novel approach for gene expression optimization through native promoter and 5' UTR combinations based on RNA-seq, Ribo-seq, and TSS-seq of *Streptomyces coelicolor*. ACS Synth. Biol. 2017, 6, 555–565.
- 41. Kim, K.S.; Lee, Y. Regulation of 6S RNA biogenesis by switching utilization of both sigma factors and endoribonucleases. *Nucleic Acids Res.* **2004**, *32*, 6057–6068. [CrossRef]
- 42. Li, Z.; Zhu, L.; Yu, Z.; Liu, L.; Chou, S.H.; Wang, J.; He, J. 6S-1 RNA contributes to sporulation and parasporal crystal formation in *Bacillus thuringiensis. Front. Microbiol.* **2020**, *11*, 604458. [CrossRef]
- Behra, P.R.K.; Pettersson, B.M.F.; Das, S.; Dasgupta, S.; Kirsebom, L.A. Comparative genomics of *Mycobacterium mucogenicum* and *Mycobacterium neoaurum* clade members emphasizing tRNA and non-coding RNA. *BMC Evol. Biol.* 2019, 19, 124. [CrossRef] [PubMed]
- 44. Hnilicova, J.; Jirat Matejckova, J.; Sikova, M.; Pospisil, J.; Halada, P.; Panek, J.; Krasny, L. Ms1, a novel sRNA interacting with the RNA polymerase core in mycobacteria. *Nucleic Acids Res.* **2014**, *42*, 11763–11776. [CrossRef] [PubMed]
- 45. Sikova, M.; Janouskova, M.; Ramaniuk, O.; Palenikova, P.; Pospisil, J.; Bartl, P.; Suder, A.; Pajer, P.; Kubickova, P.; Pavlis, O.; et al. Ms1 RNA increases the amount of RNA polymerase in *Mycobacterium smegmatis*. *Mol. Microbiol.* **2019**, *111*, 354–372.
- 46. Trotochaud, A.E.; Wassarman, K.M. 6S RNA function enhances long-term cell survival. J. Bacteriol. 2004, 186, 4978–4985. [CrossRef]
- 47. Wassarman, K.M.; Storz, G. 6S RNA regulates E. coli RNA polymerase activity. Cell 2000, 101, 613–623. [CrossRef]
- 48. Cavanagh, A.T.; Klocko, A.D.; Liu, X.; Wassarman, K.M. Promoter specificity for 6S RNA regulation of transcription is determined by core promoter sequences and competition for region 4.2 of sigma70. *Mol. Microbiol.* **2008**, *67*, 1242–1256. [CrossRef]
- 49. Neusser, T.; Polen, T.; Geissen, R.; Wagner, R. Depletion of the non-coding regulatory 6S RNA in *E. coli* causes a surprising reduction in the expression of the translation machinery. *BMC Genomics* **2010**, *11*, 165. [CrossRef]
- Ando, Y.; Asari, S.; Suzuma, S.; Yamane, K.; Nakamura, K. Expression of a small RNA, bs203 RNA, from the *yocI-yocJ* intergenic region of *Bacillus subtilis* genome. *FEMS Microbiol. Lett.* 2002, 207, 29–33. [CrossRef]
- 51. Beckmann, B.M.; Burenina, O.Y.; Hoch, P.G.; Kubareva, E.A.; Sharma, C.M.; Hartmann, R.K. In vivo and in vitro analysis of 6S RNA-templated short transcripts in *Bacillus subtilis*. *RNA Biol.* **2011**, *8*, 839–849. [CrossRef]
- Suzuma, S.; Asari, S.; Bunai, K.; Yoshino, K.; Ando, Y.; Kakeshita, H.; Fujita, M.; Nakamura, K.; Yamane, K. Identification and characterization of novel small RNAs in the *aspS-yrvM* intergenic region of the *Bacillus subtilis* genome. *Microbiology* 2002, 148, 2591–2598. [CrossRef]
- 53. Cavanagh, A.T.; Wassarman, K.M. 6S-1 RNA function leads to a delay in sporulation in *Bacillus subtilis*. J. Bacteriol. 2013, 195, 2079–2086. [CrossRef]
- 54. Warrier, I.; Hicks, L.D.; Battisti, J.M.; Raghavan, R.; Minnick, M.F. Identification of novel small RNAs and characterization of the 6S RNA of *Coxiella burnetii*. *PLoS ONE* **2014**, *9*, e100147.
- 55. Yague, P.; Rodriguez-Garcia, A.; Lopez-Garcia, M.T.; Rioseras, B.; Martin, J.F.; Sanchez, J.; Manteca, A. Transcriptomic analysis of liquid non-sporulating *Streptomyces coelicolor* cultures demonstrates the existence of a complex differentiation comparable to that occurring in solid sporulating cultures. *PLoS ONE* **2014**, *9*, e86296. [CrossRef]
- 56. Bibb, M.J.; Molle, V.; Buttner, M.J. Sigma(BldN), an extracytoplasmic function RNA polymerase sigma factor required for aerial mycelium formation in *Streptomyces coelicolor* A3(2). *J. Bacteriol.* **2000**, *182*, 4606–4616. [CrossRef] [PubMed]
- 57. Mendez, C.; Chater, K.F. Cloning of *whiG*, a gene critical for sporulation of *Streptomyces coelicolor* A3(2). *J. Bacteriol.* **1987**, *169*, 5715–5720. [CrossRef] [PubMed]
- Flardh, K.; Findlay, K.C.; Chater, K.F. Association of early sporulation genes with suggested developmental decision points in Streptomyces coelicolor A3(2). Microbiology 1999, 145 Pt 9, 2229–2243. [CrossRef]
- 59. Chater, K.F. Multilevel regulation of Streptomyces differentiation. Trends Genet. 1989, 5, 372–377. [CrossRef]
- 60. Ryding, N.J.; Kelemen, G.H.; Whatling, C.A.; Flardh, K.; Buttner, M.J.; Chater, K.F. A developmentally regulated gene encoding a repressor-like protein is essential for sporulation in *Streptomyces coelicolor* A3(2). *Mol. Microbiol.* **1998**, 29, 343–357. [CrossRef]

- 61. Becher, P.G.; Verschut, V.; Bibb, M.J.; Bush, M.J.; Molnar, B.P.; Barane, E.; Al-Bassam, M.M.; Chandra, G.; Song, L.; Challis, G.L.; et al. Developmentally regulated volatiles geosmin and 2-methylisoborneol attract a soil arthropod to *Streptomyces* bacteria promoting spore dispersal. *Nat. Microbiol.* **2020**, *5*, 821–829. [CrossRef]
- 62. Guijarro, J.; Santamaria, R.; Schauer, A.; Losick, R. Promoter determining the timing and spatial localization of transcription of a cloned *Streptomyces coelicolor* gene encoding a spore-associated polypeptide. *J. Bacteriol.* **1988**, *170*, 1895–1901. [CrossRef]
- 63. Willey, J.; Santamaria, R.; Guijarro, J.; Geistlich, M.; Losick, R. Extracellular complementation of a developmental mutation implicates a small sporulation protein in aerial mycelium formation by *S. coelicolor*. *Cell* **1991**, *65*, 641–650. [CrossRef]
- 64. Khokhlov, A.S.; Tovarova, I.I.; Borisova, L.N.; Pliner, S.A.; Shevchenko, L.N.; Kornitskaia, E.; Ivkina, N.S.; Rapoport, I.A. [The a-factor, responsible for streptomycin biosynthesis by mutant strains of actinomyces streptomycini]. *Dokl. Akad. Nauk. SSSR* **1967**, 177, 232–235.
- 65. Takano, E. Gamma-butyrolactones: *Streptomyces* signalling molecules regulating antibiotic production and differentiation. *Curr. Opin. Microbiol.* **2006**, *9*, 287–294. [CrossRef]
- Kato, J.Y.; Funa, N.; Watanabe, H.; Ohnishi, Y.; Horinouchi, S. Biosynthesis of gamma-butyrolactone autoregulators that switch on secondary metabolism and morphological development in *Streptomyces. Proc. Natl. Acad. Sci. USA* 2007, 104, 2378–2383. [CrossRef]
- 67. Hindra; Pak, P.; Elliot, M.A. Regulation of a novel gene cluster involved in secondary metabolite production in *Streptomyces coelicolor*. *J. Bacteriol.* **2010**, *192*, 4973–4982. [CrossRef]
- 68. Park, U.M.; Suh, J.W.; Hong, S.K. Genetic analysis of *absR*, a new *abs* locus of *Streptomyces coelicolor*. *J. Microbiol. Biotechnol.* **2000**, 10, 169–175.
- 69. Tenconi, E.; Traxler, M.F.; Hoebreck, C.; van Wezel, G.P.; Rigali, S. Production of prodiginines is part of a programmed cell death process in *Streptomyces coelicolor*. *Front. Microbiol.* **2018**, *9*, 1742. [CrossRef]
- Takano, H.; Obitsu, S.; Beppu, T.; Ueda, K. Light-induced carotenogenesis in *Streptomyces coelicolor* A3(2): Identification of an extracytoplasmic function sigma factor that directs photodependent transcription of the carotenoid biosynthesis gene cluster. *J. Bacteriol.* 2005, *187*, 1825–1832. [CrossRef]
- Song, L.; Barona-Gomez, F.; Corre, C.; Xiang, L.; Udwary, D.W.; Austin, M.B.; Noel, J.P.; Moore, B.S.; Challis, G.L. Type III polyketide synthase beta-ketoacyl-acp starter unit and ethylmalonyl-coa extender unit selectivity discovered by *Streptomyces coelicolor* genome mining. J. Am. Chem. Soc. 2006, 128, 14754–14755. [CrossRef]
- 72. Aoki, Y.; Matsumoto, D.; Kawaide, H.; Natsume, M. Physiological role of germicidins in spore germination and hyphal elongation in *Streptomyces coelicolor* A3(2). *J. Antibiot.* **2011**, *64*, 607–611. [CrossRef]